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Abstract 
The DMD gene resides on the X chromosome and encodes the protein 
dystrophin, a 427kD cytoplasmic protein responsible for linking the costameric 
actin cytoskeleton to the extracellular matrix via the associated dystrophin-
glycoprotein complex. Mutations in dystrophin that abolish or reduce its 
expression lead to Duchenne muscular dystrophy (DMD) or the less severe 
Becker muscular dystrophy. Patients with DMD become wheelchair bound in 
their early teens and succumb to fatal cardiac and/or respiratory failure in their 
mid-twenties to early thirties. There is currently no effective or widely available 
treatment for DMD beyond ventilatory support and the use of corticosteroids. A 
long-known but poorly understood phenotype of the dystrophin-deficient mdx 
mouse is that the subsarcolemmal microtubule lattice is disorganized, the 
consequences of which are mostly unknown. 
Many therapies for treating dystrophin deficiency aim at upregulating its 
autosomal homolog utrophin due to its structural similarity and ability to bind an 
almost identical repertoire of proteins that dystrophin binds. It was previously 
shown that utrophin cannot bind neuronal nitric oxide synthase (nNOS) even 
though dystrophin binds nNOS, establishing for the first time a functional 
difference between dystrophin and utrophin. Here, we show that transgenic 
overexpression of utrophin on the mdx mouse background (Fiona-mdx) is not 
sufficient to rescue the disorganized microtubule network of the mdx mouse. 
Moreover, transgenic overexpression of dystrophins on the mdx mouse 
background results in rescue of microtubule lattice organization. Thus, we have 
iv 
 
elucidated a second functional difference between dystrophin and utrophin. 
Additionally, Fiona-mdx mice lack full recovery of cage activity after a bout of mild 
exercise. Our results suggest that any deficiency in nNOS binding or microtubule 
lattice function caused by loss of dystrophin may not be restored by upregulation 
of utrophin. Therefore, it remains important to determine other specific 
pathologies to which aberrant nNOS localization or microtubule disorganization 
associated with loss of dystrophin protein expression contributes. 
Previously, our lab reported that dystrophin directly binds to microtubules 
and organizes them beneath the sarcolemma. Microtubules are composed of α- 
and β-tubulin monomers arranged in heterodimeric protofilaments which form a 
hollow, cylindrical tube along which the cell transports intracellular cargo using 
the motor proteins dyneins and kinesins. Using in vitro microtubule 
cosedimentation assays, we show that dystrophin binds to microtubules with 
strong affinity (KD=0.33µM). Through the use of various recombinant constructs 
tested via in vitro microtubule cosedimentation we show that spectrin-like repeats 
20-22 of the dystrophin central rod are responsible for microtubule binding 
activity. However, we show that these repeats require flanking regions of 
dystrophin for proper binding activity, making microtubule binding a context-
dependent function of dystrophin. Additionally, we show that recombinant 
utrophin does not bind microtubules in vitro, corroborating our in vivo findings of 
the disorganized subsarcolemmal microtubule lattice of the Fiona-mdx mouse. 
We also provide evidence showing that dystrophin functions as a molecular 
guidepost to organize subsarcolemmal microtubules into a rectilinear lattice. 
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 To further elucidate the function of subsarcolemmal microtubule lattice 
organization and the consequences of its disorganization, we have generated a 
transgenic mouse expressing a dystrophin incapable of microtubule binding 
activity while still maintaining all other known functions. Our initial studies show 
that the microtubule lattice of this mouse when crossed onto the dystrophin-
deficient mdx mouse background remains disorganized even in the presence of 
160% WT levels of dystrophin and the fact that transgenic dystrophin 
incorporates into the dystrophin-glycoprotein complex. This model will be useful 
for discerning phenotypes present in the Fiona-mdx mouse that are specifically 
related to microtubule disorganization since nNOS localization is intact in this 
mouse.  
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Dystrophin and Duchenne Muscular Dystrophy 
Dystrophin is a 427kD cytoplasmic protein predominantly expressed in 
striated muscle. The DMD gene, which encodes dystrophin, resides on the X 
chromosome in both humans and mice and spans over 2.4 megabases of DNA, 
making it the largest gene in any known genome (Hoffman et al., 1987). The 
genomic locus of DMD consists of 79 exons within which exist multiple tissue-
specific promoters encoding various dystrophin isoforms (Nudel et al., 1989; Bar 
et al., 1990; Górecki et al., 1992; Byers et al., 1993; Pillers et al., 1993; Roberts 
et al., 1993; Lidov et al., 1995). These isoforms include three full-length 
dystrophin isoforms expressed in cardiac muscle (Dp427c), skeletal muscle 
(Dp427m), and Purkinje cells (Dp427p); a 260kD isoform expressed in the retina 
(Dp260); a 140kD isoform expressed in the central nervous system (Dp140); a 
116kD isoform expressed in Schwann cells (Dp116); and a 71kD isoform 
expressed highly in the liver and in various other non-muscle tissues (Dp71). 
Due to its vast size, the DMD gene is statistically more prone to mutation 
than smaller genes. Mutations in dystrophin which abolish or reduce its function 
lead to Duchenne muscular dystrophy (DMD) or a milder form of the disease, 
Becker muscular dystrophy (Worton and Thompson, 1988). Approximately one in 
every 4000 boys is born with DMD (Mendell et al., 2012), all of whom will 
inevitably become wheelchair-bound and succumb to fatal cardiac arrest or 
respiratory failure during their twenties, with a small percentage reaching their 
early thirties (Rall and Grimm, 2012). Of these mutations, a portion occur de 
novo and therefore maternal screening may not be sufficient to guarantee 
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genetic fidelity. Current treatment is limited to respiratory therapy, which prolongs 
life, and corticosteroids, which are minimally effective and can cause serious side 
effects (Angelini, 2007). 
The dystrophin protein consists of an N-terminal tandem calponin-
homology domain which interacts with filamentous γ-actin; twenty-four spectrin-
like repeats with four flexible hinge regions within which lies a second actin 
binding domain and the neuronal nitric oxide synthase (nNOS) binding domain; a 
cysteine-rich domain containing WW, EF-hand, and ZZ domains known to 
interact with β-dystroglycan at the muscle plasma membrane, or sarcolemma; 
and a C-terminal domain known to interact with α-dystrobrevin and α-syntrophin 
(Koenig et al., 1988; Koenig and Kunkel, 1990; Way et al., 1992; Bork and Sudol, 
1994; Ponting et al., 1996; Rybakova and Ervasti, 1997). Each spectrin-like 
repeat is a triple alpha helical bundle, which each helix designated α1-3. In 
striated muscle, dystrophin localizes to the sarcolemma at a region referred to as 
the costamere (Porter et al., 1992) and links cytoplasmic γ-actin filaments at its 
N-terminus with β-dystroglycan at its C-terminus (Figures 1-1 and 1-2). Thus, 
dystrophin is thought to stabilize the sarcolemma during muscle contraction to 
decrease damage incurred as a result of normal muscle function. In the absence 
of dystrophin, costameric proteins mislocalize, leading to membrane instability 
(Mokri and Engel, 1998) and muscle weakness (Carlson and Makiejus, 1990). 
The protein β-dystroglycan spans the sarcolemma and interacts with 
laminin in the extracellular matrix via the heavily glycosylated α-dystroglycan 
(Ervasti and Campbell, 1993). These two proteins were initially described as 
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components of a larger protein complex eventually named the dystrophin-
glycoprotein complex (DGC) which was later shown to include the sarcoglycans, 
sarcospan, dystrobrevin, and syntrophin  (Ervasti and Campbell, 1991). The 
presence of the dystroglycans, sarcoglycans, and other DGC member proteins at 
the sarcolemma requires dystrophin and patients with DMD show reduced levels 
of these DGC component proteins in muscle biopsies. 
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Utrophin and the mdx Mouse 
Utrophin is the autosomal homolog of dystrophin (Matsumura et al., 1992; 
Kramarcy et al., 1994; Winder et al., 1995; Blake et al., 2002). In both humans 
and mice, utrophin is ubiquitously expressed in all tissues throughout 
development and adulthood. During muscle development, utrophin localizes to 
the sarcolemma where it serves the same role that dystrophin does later in 
development. However, as development progresses, utrophin is lost at the 
sarcolemma as dystrophin expression begins to rise and the former becomes 
sequestered to the neuromuscular and myotendinous junctions (Matsumura et 
al., 1992; Kramarcy et al., 1994; Winder et al., 1995; Gramolini et al., 1997; Blake 
et al., 2002). 
The utrophin gene UTRN resides on chromosome 6 in humans and 
chromosome 10 in mice. In both humans and mice, UTRN consists of 72 exons 
and spans approximately 900 kilobases of DNA (Pearce et al., 1993). The 
utrophin protein consists of an N-terminal tandem calponin-homology domain 
which interacts with filamentous γ-actin; twenty-two spectrin-like repeats with four 
flexible hinge regions, of which the first ten repeats participate in actin binding; a 
cysteine-rich domain which interacts with β-dystroglycan; and a C-terminal 
domain. The dystrophin and utrophin proteins are 85-87% similar and 74-79% 
identical in the N-terminal actin binding and cysteine rich domains, whereas the 
spectrin-like repeats show approximately 50% overall similarity (Figure 1-3). No 
human diseases have been associated with mutations in utrophin, indicating that 
it may be embryonic lethal in humans. However, a utrophin deficient mouse 
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model exists which shows no overt phenotypes aside from reduced acetylcholine 
receptor clustering at the neuromuscular junction, suggesting that utrophin 
deficiency may simply not cause disease (Deconinck, 1997). 
The mouse model most widely used to study DMD is the mdx mouse, 
which contains a nonsense mutation in exon 23 of the dystrophin transcript, 
ablating dystrophin protein expression (Bulfield et al., 1984). The relatively mild 
dystrophic phenotype of the dystrophin-deficient mdx mouse is partially credited 
to the upregulation of utrophin (Tinsley et al., 1998; Blake et al., 2002). 
Additionally, increased utrophin levels correlate with improved prognosis in DMD 
patients (Kleopa et al., 2006). Therefore, some potential therapies in 
development for treating DMD attempt to upregulate utrophin. 
While the mdx mouse does not fully recapitulate DMD patient phenotypes, 
there are many phenotypes which it does manifest. The sarcolemma has 
increased permeability based on increased uptake of Evans blue dye, a 
membrane impermeable dye, and increased serum creatine kinase levels, a 
protein normally sequestered in the cytoplasm (Menke and Jockusch, 1991; 
Clarke et al., 1993; Matsuda et al., 1995). Additionally, the mdx mouse displays 
increased muscle weakness, especially in the diaphragm muscle, accompanied 
by repetitive rounds of muscle degeneration and regeneration leading to centrally 
nucleated muscle fibers (Carlson and Makiejus, 1990; Cox et al., 1993; Warner 
et al., 2002). Lastly, the mdx mouse is highly susceptible to eccentric contraction 
induced injury, losing approximately 85-90% of its force generating capacity after 
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only five successive eccentric contractions (Moens et al., 1993; Petrof et al., 
1993). 
In addition to the aforementioned physiological phenotypes of the mdx 
mouse, there are also molecular phenotypes associated with dystrophin 
deficiency. In the absence of dystrophin, the mdx mouse shows substantial 
reduction in abundance of DGC components (Ervasti et al., 1990; Ohlendieck 
and Campbell, 1991). The increased levels of utrophin in the mdx mouse have 
been shown to associate with the DGC components to form a so-called utrophin-
glycoprotein complex (UGC), but the presence of the UGC is insufficient to 
rescue the physiological phenotypes described above (Matsumura et al., 1992). 
However, transgenic overexpression of utrophin in the mdx mouse has been 
shown to increase the amount of UGCs present at the sarcolemma and 
ameliorate all measured dystrophic parameters of the mdx mouse (Tinsley et al., 
1998), indicating that utrophin protein levels in the mdx mouse may simply be too 
low to fully compensate for the lack of dystrophin. Like dystrophin, utrophin 
couples membrane-bound dystrophin-associated proteins with costameric actin 
filaments (Matsumura et al., 1992; Rybakova et al., 2002). However, utrophin 
does not localize neuronal nitric oxide synthase to the sarcolemma (Li et al., 
2010; Lai et al., 2013) as was previously shown for dystrophin (Lai et al., 2009), 
indicating that utrophin and dystrophin are not completely interchangeable. 
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Neuronal Nitric Oxide Synthase 
 Neuronal nitric oxide synthase (nNOS) belongs to the nitric oxide synthase 
family of enzymes, which also includes endothelial nitric oxide synthase (eNOS) 
and inducible nitric oxide synthase (iNOS). Of these three genes, eNOS exists in 
four splice variants, nNOS exists in three splice variants, whereas iNOS does not 
have any splice variants (Förstermann and Kleinert, 1995). All NOS enzymes are 
responsible for catalyzing the formation of nitric oxide, which plays roles in 
vasodilation and signaling (Förstermann et al., 1994).  
nNOS is an approximately 160kD enzyme expressed in various tissues of 
the body, most notably brain, skeletal muscle, and cardiac muscle (Schmidt et 
al., 1992; Förstermann et al., 1994; Michel and Feron, 1997). In skeletal muscle, 
nNOS localizes to myotendinous junctions and to costameres (Chang et al., 
1996). These subcellular locations are hotspots for force transduction and 
signaling, strengthening the hypothesis of the proposed function of nNOS in 
signaling and vasodilation. nNOS activity is highly calcium dependent 
(Förstermann et al., 1994). At low calcium concentrations, such as those present 
in muscle at rest (100nM), nNOS is inactive. When muscle begins to contract, 
calcium concentrations rise (500nM), and nNOS becomes active. This 
corresponds well with the increased need for vasodilation of the surrounding 
vasculature to insure increased oxygen delivery to actively contracting muscle. 
In the absence of dystrophin, the costameric localization of nNOS is lost. 
This initial observation was also accompanied with data from both human and 
mouse showing that the overall expression of nNOS was reduced in the absence 
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of dystrophin (Chang et al., 1996). This led researches to begin to hypothesize 
that nNOS may be a component of the DGC. Initial evidence in support of this 
hypothesis came when syntrophin was shown to directly interact with nNOS 
(Brenman et al., 1995; Hillier, 1999). The protein syntrophin is an established 
component of the DGC that binds to the C-terminus of dystrophin (Ahn and 
Kunkel, 1995; Suzuki et al., 1995). Based on this work, nNOS was hypothesized 
to interact with dystrophin and the DGC through its interaction with syntrophin.  
Approximately ten years after these initial discoveries, spectrin-like 
repeats 16 and 17 of the central rod domain of dystrophin were shown to be 
necessary for sarcolemmal localization of nNOS (Lai et al., 2009). Mice 
expressing a dystrophin lacking these repeats failed to show sarcolemmal nNOS 
localization. Through subsequent work, utrophin was shown to lack the nNOS 
localization activity present in dystrophin, revealing the first molecular difference 
between these two closely related proteins (Li et al., 2010). The minimal nNOS 
binding domain was shown to be the α1 helix of dystrophin repeat 17 (Lai et al., 
2013). Replacing the homologous helix in utrophin with the α1 helix of dystrophin 
repeat 17 did not confer nNOS binding activity to utrophin. However, replacing 
the homologous region of utrophin with dystrophin repeats 16 and 17 conferred 
nNOS binding activity to utrophin, indicating that nNOS binding in dystrophin is 
context-dependent, relying on flanking regions in dystrophin for proper activity.  
In terms of physiology, sarcolemmal localization of nNOS is required for 
proper recovery of activity after mild exercise. When mice lacking sarcolemmal 
localization of nNOS were subjected to mild exercise, they showed greatly 
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reduced cage activity (Kobayashi et al., 2008). In the presence of sarcolemmal 
nNOS, WT mice exhibit a nominal decrease in activity after exercise. However, in 
the absence of sarcolemmal nNOS, this decrease in activity is greatly 
exacerbated. The mdx mouse shows an even greater exacerbation of this loss of 
activity, presumably due to the combined lack of nNOS and dystrophin. The 
researchers hypothesized that the lack of vasodilation in the absence of nNOS 
results in decreased oxygen delivery to muscles and thus weakness and loss of 
activity. Vasodilators such as phosphodiesterase 5A inhibitors have been shown 
to be beneficial and alleviate some of the activity loss associated with exercise 
(Kobayashi et al., 2008), providing evidence for this hypothesis. 
Since the Fiona-mdx mouse transgenically overexpresses utrophin, but 
utrophin cannot localize nNOS to the sarcolemma, we initially began our study by 
rigorously characterizing the physiological differences associated with transgenic 
overexpression of utrophin. This may be helpful in delineating the benefits and 
drawbacks associated with utrophin-based therapies for treating DMD. 
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Microtubules 
Microtubule protofilaments are composed of α- and β-tubulin heterodimers 
arranged head to tail. Eleven to thirteen of these protofilaments self-assemble 
into a hollow tube known as a microtubule (Wade and Chrétien, 1993) along 
which the motor proteins dyneins and kinesins travel in order to shuttle cargo 
throughout the cell. Microtubules are polarized, having a (-) end and (+) end. The 
(-) end is capped with a ring of γ-tubulin anchored at a structure known as the 
microtubule organizing center, whereas polymerization and depolymerization 
occur at the (+) end (Figure 1-4A). Microtubules are essential in all eukaryotic 
cells for mitosis, cell growth, and cell motility (Figure 1-4B, C, D) (Kirschner and 
Mitchison, 1986).  
Tubulin monomers are approximately 55kD in size. A single α-tubulin will 
self-assemble with a single β-tubulin monomer to form a heterodimer. Each 
monomer binds a single GTP molecule with that of β-tubulin being hydrolyzed to 
GDP over time. Since the β-tubulin monomer is exposed at the (+) end of the 
microtubule, GTP hydrolysis at the terminal β-tubulin drives the phenomenon 
known as dynamic instability (Figure 1-5). Dynamic instability refers to the fact 
that the (+) end of a microtubule will undergo long waves of relatively slow 
polymerization followed by short bursts of relatively fast depolymerization. This 
allows for rapid microtubule reorganization within the cell and is the driving force 
that separates chromosomes during cell division.  
To date, seven α-tubulin and eight β-tubulin genes have been discovered. 
Within a given family, each tubulin shows great similarity to each other except at 
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its C-terminal tail region. This region is where most tubulin posttranslational 
modifications occur. Both α- and β-tubulin are subject to posttranslational 
modifications such as detyrosination, acetylation, polyglycation, and 
polyglutamylation (Hammond et al., 2008). These posttranslational modifications 
are thought to regulate microtubule stability, polymerization dynamics, and 
protein-protein interactions, as well as provide the basis for which motors travel 
along which microtubules.  
Studies of microtubule function in striated muscle are rarer than studies in 
other tissues, but they do exist. Multiple groups have shown that proper 
microtubule function is necessary for myotube formation, which occurs when 
singly nucleated myoblast cells fuse to become multinucleated myotubes (Saitoh 
et al., 1988; Chang et al., 2002; Perez et al., 2002). Additionally, the microtubule 
(+) end binding protein EB1 has been shown to be necessary in this process 
(Zhang et al., 2009). While Golgi-derived vesicles require proper microtubule 
organization for transport throughout the cell, the Golgi itself requires proper 
microtubule organization for accurate localization and function within the cell 
(Ralston et al., 1999, 2001). Apart from these phenotypes, little is known about 
the molecular pathology of microtubule perturbations in striated muscle.  
In WT skeletal muscle, microtubules are organized into a rectilinear lattice 
beneath the sarcolemma. However, in mdx muscle tissue the microtubule lattice 
becomes disorganized (Percival et al., 2007; Ayalon et al., 2008; Prins et al., 
2009), the pathological consequences of which are mostly unknown. Recently, it 
was shown that the altered microtubule network in mdx cardiac tissue contributes 
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to increased reactive oxygen species and aberrant calcium regulation, 
suggesting that microtubule lattice derangement in the mdx mouse directly 
contributes to the molecular pathogenesis of DMD (Prosser et al., 2011; 
Khairallah et al., 2012). 
While the mdx mouse expresses increased levels of endogenous utrophin 
(Rybakova et al., 2002) the skeletal muscle microtubule lattice remains 
disorganized (Percival et al., 2007; Ayalon et al., 2008; Prins et al., 2009) 
suggesting that the microtubule binding function of dystrophin may not be 
conserved in utrophin. On the other hand, the increased endogenous utrophin 
expression in the mdx mouse is insufficient to mechanically anchor costameric 
actin filaments to the sarcolemma while transgenic utrophin overexpression 
restores coupling (Rybakova et al., 2002), indicating that utrophin protein levels 
in the mdx mouse may simply be too low to properly organize microtubules. 
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Potential Therapies for Duchenne Muscular Dystrophy 
The development of transgenic mice overexpressing utrophin on the mdx 
mouse background has provided proof of principle that utrophin upregulation can 
functionally compensate for the absence of dystrophin (Tinsley et al., 1998). 
Subsequent work has shown that the protein levels produced from expression of 
the endogenous utrophin gene can substitute for transgenic overexpression 
when upregulated. In one study, transgenic mice were created harboring artificial 
zinc-finger transcription factors targeted to the utrophin promoter. The muscle 
tissue of these mice showed a marked increase in utrophin expression and its 
presence at the sarcolemma comparable to the levels of dystrophin in WT mice 
(Mattei et al., 2007). However, since transgenic overexpression is not an option 
for treatment of humans, high throughput small molecule screens have been 
undertaken to identify drugs that could possibly be used to achieve utrophin 
overexpression. This would offer systemic delivery of a drug to patients and 
would require no genetic manipulation to achieve therapeutic benefit.  
 Nonsense mutations account for 35-40% of mutations in the dystrophin 
gene (Roberts et al., 1994). Dystrophin mRNA harboring these nonsense 
mutations can cause nonsense mediated decay of the mRNA or, if translated, 
produces a truncated protein that at minimum lacks the C-terminal β-
dystroglycan binding domain, rendering it incapable of coupling muscle 
contraction with force transmission. Earlier studies on the antibiotic gentamicin 
showed that it could cause the ribosome to skip over nonsense mutations and 
allow for full translation of the otherwise intact mRNA (Barton-Davis et al., 1999). 
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These findings opened the door for high throughput screens aimed at finding 
nonsense mutation read-through drugs that could be used not only to treat DMD 
patients with nonsense mutations but other diseases caused by these mutations. 
Drawbacks to this type of therapy are that drugs would have to be administered 
for the life of the patient, which can be rather costly. In addition, 60-65% of DMD 
patients would not benefit from this therapy since their mutations are not 
nonsense mutations. 
 As an alternative to drugs that allow read-through of nonsense mutations, 
exon skipping provides a means to bypass the exon harboring the nonsense 
mutation altogether. This therapeutic strategy can be employed not only for 
nonsense mutations, but also missense mutations that may affect protein folding 
or stability as well as insertions or deletions that may affect the reading frame of 
the mRNA. It is important to note that in order to remain in frame it may be 
necessary to bypass multiple exons. Blocking splice site recognition can be 
achieved by using antisense oligonucleotides or oligonucleotide mimics such as 
morpholino oligomers, which have a modified backbone in place of the normal 
phosphate backbone (van Deutekom et al., 2001). These modified oligomers 
have a longer half-life since their composition is not one the cell normally 
encounters, which reduces the likelihood they will be degraded. In one study, 
exon 23 of the mdx mouse was targeted for skipping using morpholinos (Yin et 
al., 2009). The mdx mice treated with these morpholinos expressed sarcolemma-
associated dystrophin in multiple muscle tissues and this increased expression 
correlated with increased grip strength, reduced serum creatine kinase levels, 
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and fewer centrally nucleated fibers, all of which point to phenotypic restoration 
toward that of WT mice. 
 Restoration of dystrophin expression can also be achieved by cellular 
introduction of full-length or truncated dystrophin constructs. Since a new, normal 
dystrophin gene is introduced to the cell, gene delivery bypasses the need for 
personalized therapy based on individual patient mutations, which is an 
advantage over exon skipping therapies. Viral-mediated transduction is the most 
prominent method of gene delivery. Earlier methods, such as direct intramuscular 
injection of plasmid DNA coding for dystrophin, showed very poor efficacy and is 
not very amenable to humans as injection of every muscle cell is not feasible 
(Acsadi et al., 1991). However, these initial experiments provided proof of 
principle. Recombinant adeno-associated virus (rAAV) has become the main viral 
vehicle used for delivering dystrophin DNA in a systemic manner. However, the 
limited carrying capacity of rAAV prevents the full-length dystrophin construct 
from being transduced. Therefore, truncated versions of dystrophin harboring 
deletions in the internal rod domain and/or the C-terminus were used.  
 Finally, systemic delivery of dystrophin or utrophin protein can potentially 
treat DMD patients. Since it is not plausible to inject every muscle cell with 
protein directly, some method of allowing the protein to enter the cell must be 
devised. One potential solution to this issue comes from the lysine-rich domain of 
the HIV-1 transactivator of transcription (TAT) protein. When fused to a  protein 
of interest, this sequence allows for cellular entry of the entire protein via 
macropinocytosis (Schwarze et al., 2000). Fusing TAT to dystrophin or utrophin 
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and injecting it intraperitoneally or intravenously allows for systemic delivery of 
recombinant protein that will be able to traverse cell membranes. Functional 
recovery of the dystrophic phenotype in mdx mice treated with a fusion protein of 
TAT and a truncated version of utrophin (TAT-microutrophin) has proven 
effective (Sonnemann et al., 2009). Intraperitoneal injection of TAT-microutrophin 
showed that it entered all organs, including skeletal and cardiac tissue, and was 
found to localize to the sarcolemma. This sarcolemmal localization coincided with 
restoration of the normal glycoprotein complex along with increased grip strength 
and decreased susceptibility to contraction-induced injury. 
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Figures 
 
 
 
 
 
 
 
 
Figure 1-1: The dystrophin-glycoprotein complex. Schematic representation 
of the dystrophin-glycoprotein complex. From Davies and Nowak, 2006.  
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Figure 1-2: Schematic representation of a muscle fiber. Representative 
structure of a single muscle fiber. Dystrophin is highly enriched at costameres 
where it links cytoplasmic γ-actin with transmembrane β-dystroglycan. This 
linkage is thought to stabilize the sarcolemma during muscle contraction to 
prevent damage. From Ervasti, 2003. 
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Figure 1-3: Homology between dystrophin and utrophin. Schematic 
representation showing percentage similarity and identity of homologous regions 
of dystrophin and utrophin. From Ervasti, 2007. 
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Figure 1-4: Structure and cellular functions of microtubules. (A) Schematic 
representation of the structure of a microtubule. α- and β-tubulin heterodimers 
self-assemble into protofilments which then self-assemble into hollow 
microtubules. IN cells, microtubules are capped at their (-) end by a ring of γ-
tubulin, which is then anchored to the microtubule organizing center (pink, purple, 
and black). (B) During cytokinesis, microtubules are responsible for separating 
sister chromatids at the cleavage furrow. (C) Intracellular vesicle transport 
between the nucleus, Golgi complex, endoplasmic reticulum, and plasma 
membrane requires motor movement along microtubules. (D) Movement in many 
microorganisms relies on the movement of dynein motors along microtubule 
doublets in specialized structures known as flagella or cilia. 
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Figure 1-5: Model of microtubule dynamic instability. Microtubule (+) end 
dynamics are regulated by the presence of either GTP or GDP at the terminal β-
tubulin subunit. When in the GTP-bound state, the microtubule continues to 
polymerize steadily. When in the GDP-bound state, the microtubule undergoes 
rapid depolymerization. The switch from polymerization to depolymerization is 
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known as catastrophe whereas the reverse is known as rescue. Rescue occurs 
via the addition of a GTP-bound heterodimer to the depolymerizing (+) end, 
which can be accomplished by microtubule interacting proteins. Adapted from 
Akhmanova and Steinmetz, 2008.  
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Chapter Two 
Analysis of Differences between Dystrophin and Utrophin 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Joseph Belanto performed all experiments except for the following: The data 
presented in Figures 2-5 and 2-6 were generated by Michael Eckhoff, Tara 
Mader, and Dr. Dawn Lowe. Dr. Kay E. Davies provided Fiona mice and Dr. 
Jeffrey S. Chamberlain provided Dys-TG-mdx and mini-Dys-TG-mdx mice. 
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Summary 
Dystrophin and utrophin are highly homologous proteins capable of linking 
subsarcolemmal γ-actin filaments in the cytoplasm with laminin in the 
extracellular matrix via the heavily glycosylated transmembrane β-dystroglycan. 
Despite exhibiting several overlapping functions, endogenous dystrophin and 
utrophin occupy different subcellular locations within muscle cells: dystrophin 
resides primarily at costameres whereas utrophin localizes to the neuromuscular 
and myotendinous junctions. In DMD patients who lack dystrophin, utrophin 
protein is upregulated and can be found in place of dystrophin at costameres. 
Unfortunately, this utrophin upregulation is insufficient to fully compensate for the 
absence of dystrophin. However, transgenic overexpression of utrophin has 
proven effective in ameliorating dystrophin-deficiency in mice and is therefore 
being pursued as a potential therapy to treat DMD. Here, we rigorously analyzed 
different mouse models to determine which, if any, phenotypes of the dystrophin-
deficient mdx mouse remain in the presence of transgenically overexpressed 
utrophin. We find that utrophin cannot compensate for dystrophin in regards to 
subsarcolemmal microtubule lattice organization, recovery of activity after mild 
exercise, or loss of torque production after eccentric contraction. Therefore, we 
conclude that while utrophin-based therapies for DMD will provide great benefit, 
they will not ameliorate all DMD patient phenotypes. 
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Introduction 
Duchenne muscular dystrophy (DMD) is a lethal X-linked disease found in 
approximately one of every 5000 live male births (Mendell et al., 2012). DMD is 
caused by loss of function mutations in the DMD gene which encodes the protein 
dystrophin (Hoffman et al., 1987). Dystrophin binds cytoplasmic γ-actin filaments 
at its N-terminus and second third of the central rod domain to link them to β-
dystroglycan at its C-terminus. Through this interaction dystrophin is 
hypothesized to reduce normally incurred muscle damage via stabilization of the 
sarcolemma during muscle contraction. Full-body muscle weakness (Carlson and 
Makiejus, 1990) is a hallmark of dystrophin deficiency and usually manifests in 
the first decade of life as the initial missed developmental milestone.  
The mdx mouse faithfully models some of the phenotypes associated with 
DMD and is the most widely used mouse model to study DMD (Bulfield et al., 
1984). Similar to DMD patients, the mdx mouse displays widespread muscle 
weakness, undergoes repetitive rounds of muscle degeneration and regeneration 
(Carlson and Makiejus, 1990; Cox et al., 1993; Warner et al., 2002), and is highly 
susceptible to eccentric contraction induced injury, losing almost all force 
generating capacity after multiple contractions (Moens et al., 1993; Petrof et al., 
1993). However, the mdx mouse has a normal lifespan and has an overall milder 
phenotype than DMD patients, indicating that the mouse may have better 
compensatory mechanisms than humans for dealing with dystrophin deficiency. 
We and others (Ralston et al., 1999; Percival et al., 2007; Ayalon et al., 
2008; Prins et al., 2009) have shown that skeletal muscle microtubules are 
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organized into a rectilinear lattice beneath the sarcolemma and that loss of 
dystrophin in the mdx mouse results in a loss of this microtubule organization. 
While the mdx mouse expresses increased levels of endogenous utrophin 
(Rybakova et al., 2002) the skeletal muscle microtubule lattice remains 
disorganized (Percival et al., 2007; Ayalon et al., 2008; Prins et al., 2009) 
suggesting that the microtubule binding function of dystrophin may not be 
conserved in utrophin. On the other hand, the increased endogenous utrophin 
expression in the mdx mouse is insufficient to mechanically anchor costameric 
actin filaments to the sarcolemma while transgenic utrophin overexpression 
restores coupling (Rybakova et al., 2002), indicating that utrophin protein levels 
in mdx mice may simply be too low to properly organize microtubules. This raises 
the question as to whether dystrophin and utrophin are completely 
interchangeable in regards to this and other molecular and physiological 
functions.  
One established phenotype of the Fiona-mdx mouse, a mouse model 
which transgenically overexpresses full-length utrophin on the dystrophin-
deficient mdx mouse background, is that neuronal nitric oxide synthase (nNOS) 
does not localize to the sarcolemma whereas localization occurs in the presence 
of dystrophin (Lai et al., 2009; Li et al., 2010), indicating that utrophin cannot fully 
compensate for the lack of dystrophin. While the Fiona-mdx mouse has been 
analyzed for various dystrophic phenotypes, a rigorous evaluation of other 
possible phenotypes is lacking. Here, we have performed experiments to further 
elucidate phenotypes of the mdx mouse that specifically associated with the loss 
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of nNOS localization and/or microtubule disorganization. To do this, we have 
utilized the Dys-TG-mdx mouse (nNOS localization, microtubule organization), 
the mini-Dys-TG-mdx mouse (no nNOS localization, microtubule organization), 
and the Fiona-mdx mouse (no nNOS localization, no microtubule organization). 
We find that loss of nNOS localization regardless of microtubule organization 
contributes to loss of activity after mild exercise whereas loss of microtubule 
organization regardless of nNOS localization contributes to torque loss following 
eccentric contraction in anterior muscles. 
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Results 
In this study, we utilized three previously developed transgenic mouse 
models crossed onto the dystrophin-deficient mdx mouse background. The first 
transgenically overexpresses full-length utrophin (Fiona-mdx), the second  
transgenically overexpresses nearly full-length dystrophin (Dys-TG-mdx), and the 
last transgenically overexpresses a miniaturized dystrophin (mini-Dys-TG-mdx) 
lacking spectrin-like repeats 4 to 19 (Tinsley et al., 1998; Crawford et al., 2000; Li 
et al., 2006). Western blotting of quadriceps tissue lysates verified that the 
transgenic proteins were being overexpressed above WT levels in all transgenic 
lines (Figure 2-1). To begin to address which molecular and physiological 
phenotypes of the mdx mouse are not rescued be transgenic overexpression of 
utrophin or dystrophin, we first analyzed microtubule lattice organization in 
different mouse models (Figure 2-2). Unlike WT mice, which show 
subsarcolemmal microtubule lattice organization (Figure 2-2A), we find that the 
microtubule lattice in the Fiona-mdx mouse remained disorganized with 
morphology similar to that seen in the mdx mouse (Figure 2-2B, C). The Dys-TG-
mdx and mini-Dys-TG-mdx mice showed rescued microtubule lattice organization 
qualitatively comparable to that of WT mice (Figure 2-2D, E). These data indicate 
that transgenic utrophin overexpression in skeletal muscle is insufficient to 
organize the microtubule cytoskeleton in the mdx mouse. Interestingly, 
microtubules remained organized in both WT and mdx mice in the interior of 
muscle fibers (Figure 2-3), a cellular location in which dystrophin is absent, 
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indicating that interior organization may be mediated by a different protein or set 
of proteins present in both WT and mdx mice.  
To elucidate other phenotypes of the Fiona-mdx mouse potentially related 
to the loss of nNOS localization or microtubule lattice organization, we first 
evaluated physical activity after mild exercise to assess activity-induced 
inactivity. The Campbell group has established that the mdx mouse shows 
greatly reduced physical activity after mild exercise (Kobayashi et al., 2008), but 
the effect of transgenic overexpression of utrophin or dystrophin had yet to be 
evaluated. Similar to previously reported data (Kobayashi et al., 2008), we find 
that WT mice were approximately 50% less active following mild treadmill 
exercise whereas mdx mice were 95% less active (Figure 2-4). The Dys-TG-mdx 
mouse showed activity comparable to that of WT mice after mild exercise (not 
statistically different from each other). However, the Fiona-mdx and mini-Dys-TG-
mdx mice both showed intermediate loss of activity, each having approximately 
25% of initial activity (not statistically different from each other). WT mice and 
Dys-TG-mdx mice were both statistically different from Fiona-mdx and mini-Dys-
TG-mdx mice and all four lines were statistically different from mdx mice. These 
data indicated that while transgenic overexpression of utrophin in mdx mice 
significantly improves activity after mild exercise, it does not restore activity to 
levels measured after transgenic dystrophin overexpression. Interestingly, the 
mini-Dys-TG-mdx mouse, which shows rescued microtubule morphology (Figure 
2-2E), but lacks the nNOS binding domain (Li et al., 2010) mirrors the phenotype 
of the Fiona-mdx mouse, suggesting that loss of nNOS localization contributes to 
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mild exercise-induced inactivity whereas microtubule lattice organization does 
not.  
Next, we narrowed our focus down from the phenotypic characteristics of 
the entire animal to examining specific muscle groups. We began by measuring 
the force production in isolated extensor digitorum longus muscles after repeated 
eccentric contractions. Eccentric contractions occur when a muscle is being 
forcibly lengthened while it is contracting. In this assay, mdx mice begin to show 
statistically significant loss of force production after a single eccentric contraction 
(Figure 2-5), which plateaus to 15% of WT force production after five eccentric 
contractions. Comparison of Fiona-mdx and Dys-TG-mdx mice revealed no 
statistically significant force loss, even after ten consecutive eccentric 
contractions. These data indicate that transgenic overexpression of utrophin can 
compensate for the loss of dystrophin in regards to force production in isolated 
extensor digitorum longus muscles after repeated eccentric contractions.  
Subsequently, we measured torque production in vivo in the anterior 
(extensor digitorum longus and tibialis anterior) and the posterior (soleus and 
gastrocnemius) muscle groups of live mice after subjecting muscles to repeated 
rounds of eccentric contraction. In these assays, mdx mice showed drastic loss 
of torque production as compared to WT mice (Figure 2-6) in both the anterior 
and posterior muscle groups. The Dys-TG-mdx mice showed no loss of torque 
production as compared to WT mice in either muscle group. Conversely, the 
Fiona-mdx mice showed intermediate loss of torque production in the anterior 
muscle group (Figure 2-6A) but normal torque production in the posterior muscle 
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group (Figure 2-6B). This intermediate loss of torque production mirrors the 
intermediate loss of activity we observed after mild exercise in the Fiona-mdx 
mice (Figure 2-4). However, mini-Dys-TG-mdx mice do not show this 
intermediate loss of torque production in the anterior muscle group, which is in 
contrast to the loss of exercise-induced inactivity seen for these mice (Figure 2-
4). For the anterior muscle group, WT mice, Dys-TG-mdx mice, and mini-Dys-
TG-mdx mice are statistically different from Fiona-mdx mice and all mice are 
statistically different from mdx mice. Interestingly, the mini-Dys-TG-mdx mouse, 
which shows rescued microtubule morphology (Figure 2-2E), but lacks the nNOS 
binding domain (Li et al., 2010) does not mirror the phenotype of the Fiona-mdx 
mouse, suggesting that microtubule disorganization rather than loss of nNOS 
localization contributes to loss of torque production in the anterior muscles. 
One final phenotype of the mdx mouse that we thought was possibly 
linked to either the loss of nNOS localization or loss of microtubule organization 
is patterning of the neuromuscular junction (Lyons and Slater, 1991). A 
neuromuscular junction occurs at the location where a motor neuron innervates a 
muscle fiber. At this synapse, the sarcolemma is extensively folded, acetylcholine 
receptors are highly concentrated, and myonuclei tend to cluster. These 
myonuclei are specialized and upregulate the transcription of certain genes not 
highly expressed in other myonuclei, such as utrophin (Gramolini et al., 1997). In 
WT mice, the neuromuscular junction patterning appears much like a pretzel, 
folding in upon itself (Figure 2-7A). In contrast, the neuromuscular junction of the 
mdx mouse loses this patterning and instead appears like a cluster of grapes 
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(Figure 2-7B). The neuromuscular junction of the Fiona-mdx mouse was 
qualitatively similar to that of WT mice, as was the neuromuscular junction of the 
Dys-TG-mdx mouse (Figure 2-7C, D), indicating that transgenic overexpression 
of utrophin ameliorates the aberrant neuromuscular junction patterning seen in 
mdx mice. 
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Discussion 
 Many DMD therapies in development aim to upregulate endogenous 
utrophin as a surrogate for dystrophin. This approach has the theoretical 
advantage of bypassing any immune response that may develop against 
dystrophin, since a DMD patient’s immune system may identify dystrophin as 
foreign (Wang et al., 2007; Mendell et al., 2010; Flanigan et al., 2013). 
Additionally, DMD patients already harbor an intact, functional utrophin gene, so 
there is no need for genetic manipulation, only transcriptional or translational 
upregulation. However, utrophin cannot bind nNOS (Li et al., 2010) or 
microtubules (Figure 2-2C) and thus may lack other previously overlooked 
functions of dystrophin. Therefore, we sought to identify previously unknown 
pathologies of DMD that cannot be compensated for by transgenic 
overexpression of utrophin. 
The proper sarcolemmal localization of nNOS to the sarcolemma has 
been implicated in vasodilation to increase oxygen delivery to muscle during 
exercise. The lack of nNOS localization leads to decreased blood flow to the 
muscles and subsequently exercised-induced fatigue. Mice specifically lacking 
nNOS exhibit reduced cage activity after mild exercise, which is exacerbated in 
mdx mice (Kobayashi et al., 2008), presumably due to the additional lack of 
dystrophin. Here we show for the first time that transgenic overexpression of 
utrophin partially rescues this phenotype of the mdx mouse, but does restore 
activity to WT levels. Our data suggests that utrophin cannot fully substitute for 
dystrophin in maintaining activity after exercise most probably due to a lack of 
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nNOS localization at the sarcolemma. In support of this hypothesis, transgenic 
overexpression of mini dystrophin shows the same intermediate recovery of 
activity after mild exercise. This mouse also lacks sarcolemmal nNOS 
localization, but unlike the Fiona-mdx mouse, mini-Dys-TG-mdx mice show 
recovery in microtubule lattice organization (Figure 2-2). We conclude that 
exercise-induced inactivity is principally caused by loss of nNOS localization 
rather than by microtubule lattice disorganization. 
Increased reactive oxygen species and aberrant calcium regulation have 
been proposed to stem from microtubule lattice derangement in the mdx mouse, 
providing the first evidence for a pathological microtubule-associated phenotype 
in DMD (Prosser et al., 2011; Khairallah et al., 2012). Here, we show that lack of 
microtubule organization also contributes to loss of torque production in anterior 
crural muscles. The Fiona-mdx mouse loses torque production after eccentric 
contractions in vivo whereas the mini-Dys-TG-mdx mouse retains WT levels of 
torque production. We conclude that contraction-induced torque loss of anterior 
crural muscles is associated with microtubule disorganization rather than nNOS 
mislocalization.  
Since transgenic overexpression of utrophin fails to rescue nNOS 
localization and microtubule disorganization, and the mini-Dys-TG-mdx mouse 
restores microtubule lattice organization (Figure 2-2E) but does not restore 
nNOS localization to the sarcolemma (Li et al., 2010), we utilized these mouse 
lines to begin to distinguish between nNOS-associated and microtubule-
associated phenotypes. We show, for the first time, that exercise-induced 
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inactivity following mild exercise is an nNOS-associated phenotype whereas loss 
of torque production in anterior crural muscles is a microtubule-associated 
phenotype. However, a caveat to these findings is that the field lacks a mouse 
model which restores nNOS localization but fails to rescue microtubule lattice 
disorganization. The appendix outlines the generation of a mouse model to 
address this issue.  
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Figures 
 
 
Figure 2-1: Western blotting for dystrophin and utrophin in transgenic 
mouse lines. (A) The mdx mouse expresses approximately 250% of WT levels 
of utrophin in the absence of dystrophin expression. The Fiona-mdx mouse 
expresses approximately 1000% of WT levels of utrophin and 400% of mdx 
levels of utrophin. The Dys-TG-mdx mouse express approximately 300% of WT 
levels of dystrophin. Tubulin and actin shown as loading controls. (B) The mini-
Dys-TG-mdx mouse expresses approximately 600% of WT levels of dystrophin. 
Full-length dystrophin is 427kD whereas mini dystrophin is approximately 220kD. 
Actin shown as a loading control. All lanes are 60µg of total quadriceps lysate. 
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Figure 2-2: Mouse extensor digitorum longus muscle sarcolemmal 
microtubule imaging. (A) When dystrophin is present (WT), microtubules are 
organized into a rectilinear lattice beneath the sarcolemma. (B) In the absence of 
dystrophin (mdx), the microtubule lattice becomes disordered. (C) Transgenic 
overexpression of utrophin in the absence of dystrophin (Fiona-mdx) does not 
rescue the disorganized microtubule lattice. (D) Transgenic expression of nearly 
full-length dystrophin in the absence of endogenous dystrophin (Dys-TG-mdx) 
results in an organized microtubule lattice. (E) Transgenic expression of mini 
dystrophin (mini-Dys-TG-mdx) also rescues the microtubule lattice. Single 
extensor digitorum longus muscle fibers were mechanically teased from 
profusion fixed mice and immunostained for tubulin and counterstained with 
DAPI to visualize nuclei. Bar, 20µm. 
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Figure 2-3: Mouse extensor digitorum longus muscle internal microtubule 
imaging. All images are of the same fiber. A and C are from opposite faces of 
the same fiber whereas B images the same fiber internally. (A) and (C) 
Subsarcolemmal microtubule lattice is disorganized in the mdx mouse. (B)  
Interior microtubule lattice is normal. A is the same image as from Figure 2-2B. 
Bar, 20µm. 
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Figure 2-4: Activity following mild treadmill exercise. WT mice exhibited 
approximately 50% of initial activity after mild exercise whereas post-exercise 
activity in mdx mice dropped greater than 95% of their initial activity. Transgenic 
overexpression of dystrophin in mdx mice (Dys-TG-mdx) restored post-exercise 
activity levels similar to WT whereas transgenic overexpression of utrophin 
(Fiona-mdx) or mini dystrophin (mini-Dys-TG-mdx) yielded intermediate (~25%) 
restoration of activity.  Post exercise activity levels in WT mice and Dys-TG-mdx 
mice were not statistically different from each other, but were statistically different 
from Fiona-mdx and mini-Dys-TG-mdx mice, which were not statistically different 
from each other, and all 4 lines were statistically different from mdx mice 
(p<0.05). 
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Figure 2-5: Ex vivo force loss in isolated EDL muscles. Statistically significant 
loss of force production (p<0.05) in mdx mice as compared to WT mice occurs 
after a single eccentric contraction. Examining Fiona-mdx and Dys-TG-mdx mice 
revealed no statistically significant force loss, even after ten consecutive 
eccentric contractions. 
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Figure 2-6: In vivo torque loss in anterior and posterior muscle groups. (A) 
As compared to WT mice, mdx mice showed drastic loss of torque production in 
the anterior muscle group. Additionally, Dys-TG-mdx and mini-Dys-TG-mdx mice 
showed no loss of torque production as compared to WT mice. Conversely, the 
Fiona-mdx mice showed intermediate loss of torque production in the anterior 
muscle group, comparable to intermediate loss of activity seen in Figure 2-4. WT, 
Dys-TG-mdx and Fiona-mdx mice (not statistically different from each other) are 
statistically different from mdx mice. p<0.05 for all statistically significant 
differences. (B) As compared to WT mice, mdx mice showed drastic loss of 
torque production in the posterior muscle group. Additionally, Fiona-mdx mice 
and Dys-TG-mdx mice showed no loss of torque production as compared to WT 
mice. WT, Dys-TG-mdx and mini-Dys-TG-mdx mice (not statistically different 
from each other) are statistically different from Fiona-mdx mice and all mice are 
statistically different from mdx mice. p<0.05 for all statistically significant 
differences. 
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Figure 2-7: Mouse neuromuscular junction imaging. (A) Neuromuscular 
junction morphology in a WT mouse resembles a pretzel. (B) This morphology is 
lost in the mdx mouse and instead appear as a cluster of grapes. (C) The Fiona-
mdx mouse shows rescued neuromuscular junction morphology. (D) The Dys-
TG-mdx mouse shows rescued neuromuscular junction morphology. Bar, 5µm. 
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Chapter Three 
Dystrophin Repeats 20-22 Act as a Context-Dependent Molecular 
Guidepost to Organize Microtubules 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Joseph Belanto purified all proteins and performed all experiments except for the 
following: Katrina Rhett performed all differential scanning fluorimetry 
experiments.  
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Summary 
Dystrophin links the cortical actin cytoskeleton of striated muscle to the 
extracellular matrix via the dystrophin-glycoprotein complex. Mutations in 
dystrophin that abolish or reduce its function/expression lead to Duchenne or 
Becker muscular dystrophy. Dystrophin also directly binds to microtubules, and 
its absence results in microtubule disorganization, which contributes to disease 
pathology. Here we show that the dystrophin homolog utrophin lacks microtubule 
binding activity in vitro. By analyzing a series of deletion and chimeric dystrophin 
constructs, we have mapped the microtubule binding domain to spectrin-like 
repeats 20-22, but find that binding activity is context-dependent. In vitro analysis 
revealed that dystrophin stalled microtubule polymerization, but had no effect on 
microtubule dynamics when measured in bulk solution. We conclude that 
dystrophin functions as a context-dependent molecular guidepost to organize the 
subsarcolemmal microtubule lattice in skeletal muscle. 
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Introduction 
Dystrophin is a 427kD cytoplasmic protein predominantly expressed in 
striated muscle (Hoffman et al., 1987). Loss of function mutations in dystrophin 
lead to the disease Duchenne muscular dystrophy (DMD), an X-linked lethal 
disease with no cure (Worton and Thompson, 1988). The dystrophin protein 
interacts with cytosplasmic and membrane-spanning proteins such as 
filamentous γ-actin, intermediate filament proteins, neuronal nitric oxide synthase 
(nNOS), β-dystroglycan, α-dystrobrevin and α-syntrophin (Koenig et al., 1988; 
Koenig and Kunkel, 1990; Way et al., 1992; Bork and Sudol, 1994; Ponting et al., 
1996; Rybakova and Ervasti, 1997). Our lab previously showed that in addition to 
the aforementioned molecular interactions, dystrophin directly interacts with 
microtubules (Prins et al., 2009), suggesting classification of dystrophin as a 
cytolinker. 
Microtubules have not been as intensely studied in striated muscle as in 
other tissues. However, the available studies reveal that microtubules are 
essential in muscle for myotube formation, the process by which single muscle 
cells fuse to form elongated, multinucleated muscle fibers (Saitoh et al., 1988; 
Chang et al., 2002; Perez et al., 2002). Additionally, proper microtubule function 
is required for correct Golgi localization and function within muscle cells (Ralston 
et al., 1999, 2001). In WT skeletal muscle, microtubules are organized into a 
rectilinear lattice beneath the sarcolemma. However, in mdx muscle tissue the 
microtubule lattice becomes disorganized, the pathological consequences of 
which are mostly unknown. Recently, it was shown that the altered microtubule 
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network in mdx cardiac tissue contributes to increased reactive oxygen species 
and aberrant calcium regulation, suggesting that microtubule lattice derangement 
in the mdx mouse directly contributes to the molecular pathogenesis of DMD 
(Prosser et al., 2011; Khairallah et al., 2012). 
The protein ankyrin-B simultaneously interacts with dystrophin, β2-
spectrin, and dynactin-4, and is thought to deliver dystrophin to the sarcolemma 
via the microtubule cytoskeleton. Once at the sarcolemma, proper localization of 
dystrophin to the costamere requires ankyrin-G (Ayalon et al., 2008, 2011). Most 
recently, it was shown that proper localization of ankyrin-B to the sarcolemma 
relies on the scaffolding protein obscurin, underscoring the large interplay of 
proteins required for proper localization of dystrophin to costameres (Randazzo 
et al., 2013). Knockdown or knockout studies of ankyrin-B, ankyrin-G, β2-
spectrin, dynactin-4, and obscurin have shown that each is required for proper 
costameric localization of dystrophin, and that lack of this localization leads to 
phenotypes similar to those seen in the dystrophin-deficient mdx mouse (Ayalon 
et al., 2008, 2011; Randazzo et al., 2013).  
 The minimal microtubule binding domain of dystrophin has not been 
biochemically established. Initial studies from our lab indicated that dystrophin 
repeat 24 and hinge 4 were necessary for microtubule binding; however, these 
assays were performed using whole muscle microtubule cosedimentation assays 
in which other proteins may facilitate indirect protein-protein interactions (Prins et 
al., 2009). Therefore, we set out to express and purify various dystrophin 
isoforms and deletion constructs to biochemically determine the minimal 
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domain(s) within dystrophin necessary for microtubule binding activity. We find 
dystrophin repeat 24 and hinge 4 do not directly participate in microtubule 
binding activity. Instead, repeats 20-22 of dystrophin are the minimal microtubule 
binding domain. Additionally, we show that this microtubule binding is context-
specific insofar as it is dependent on flanking regions of dystrophin for proper 
function. 
 In addition to delineating the minimal microtubule binding domain in 
dystrophin, we show that in accordance with our previous mouse studies, 
recombinant utrophin cannot bind microtubules in vitro. Our results also 
demonstrate that dystrophin functions as a context-dependent molecular 
guidepost for microtubule lattice organization through a direct interaction of 
spectrin-like repeats 20-22 and microtubules, providing a molecular mechanism 
for subsarcolemmal microtubule lattice organization. 
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Results 
To begin to elucidate the microtubule binding properties of dystrophin, we 
expressed and purified full-length recombinant mouse dystrophin and utrophin 
(Rybakova et al., 2002, 2006) for comparison of microtubule binding activity in 
vitro using a microtubule cosedimentation assay (Figure 3-1A). Dystrophin 
displayed specific, high affinity binding to microtubules (KD=0.33µM) similar to 
previously published data for Dp260 (Prins et al., 2009) while utrophin showed no 
concentration-dependent, saturable binding (Figure 3-1B). Additionally, we 
analyzed both constructs via differential scanning fluorimetry (DSF) to determine 
whether they had similar thermal stabilities (Niesen et al., 2007). Both dystrophin 
and utrophin displayed a single, cooperative DSF transition, indicating well-folded 
proteins with similar melting temperatures (Figure 3-1C and Table 3-1). These 
data indicate that dystrophin binds microtubules with high affinity in a 
concentration-dependent, saturable manner and that utrophin does not exhibit 
any microtubule binding activity in vitro. 
To identify the regions of dystrophin necessary for interaction with 
microtubules, we measured microtubule binding activity in an array of naturally 
occurring dystrophin isoforms, truncation, and internal deletion constructs (Figure 
3-2). Only full-length dystrophin (KD=0.33µM), Dp260 (KD=0.26µM), and mini Dys 
(KD=0.38µM) showed specific microtubule binding (Figure 3-3). While the three 
microtubule binding constructs share a large region of dystrophin spanning from 
hinge 3 to the C-terminus, other constructs containing this same region, such as 
Dys 18-CT, failed to bind microtubules. Therefore, we used DSF to analyze all 
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constructs to determine if they had similar melting temperatures. Most constructs 
gave similar results as full-length dystrophin (Figure 3-4 and Table 3-1). 
However, Dp140, Dp116, Dys 15-24, and Dys 18-CT displayed DSF denaturation 
curves with two distinct melting temperatures (Figure 3-4 and Table 3-1). We 
hypothesized that Dp140, Dp116, Dys 15-24, and Dys 18-CT adopted 
conformations that prevent their binding to microtubules and eliminated them 
from our delineation of the microtubule binding domain. Based on data for the 
remaining constructs, we hypothesize that the microtubule binding domain of 
dystrophin resides within repeats 20-24. 
To test the roles of dystrophin repeats 20-24 in microtubule binding activity 
and to determine their sufficiency in conferring microtubule binding activity, we 
substituted dystrophin repeats 20-24 for the homologous repeats of utrophin, 
repeats 18-22 (Figure 3-5). Using the in vitro microtubule cosedimentation assay, 
Dys R20-24Utr displayed no specific microtubule binding activity, indicating that a 
region present within repeats 20-24 was necessary for microtubule binding 
activity. However, Utr R18-22Dys, in which utrophin repeats 18-22 were 
exchanged for dystrophin repeats 20-24, displayed no specific microtubule 
binding activity, indicating that dystrophin repeats 20-24 were not sufficient for 
microtubule binding activity. Together these data indicated that a region within 
dystrophin repeats 20-24 was necessary but not sufficient for microtubule binding 
activity. 
To define the minimal microtubule binding domain within dystrophin 
repeats 20-24, we constructed multiple Dp260 deletion constructs in which single 
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dystrophin repeats were deleted (Figure 3-6A) and hybrid constructs in which 
varying numbers of homologous utrophin repeats were substituted into Dp260 
(Figure 3-7A). Dp260 was chosen as a template rather than full-length dystrophin 
due to its smaller size, ease of cloning, higher protein expression, and similar 
microtubule binding characteristics to those of full-length dystrophin. All 
constructs tested were analyzed by DSF and shown to have melting 
temperatures similar to those of Dp260 (Figures 3-6B and 3-7B and Table 3-1). 
Individual deletion of each repeat within dystrophin repeats 20-24 did not 
appreciably affect the microtubule binding activity of Dp260 (Figure 3-6A and 
Table 3-1), indicating that no single repeat acts as the microtubule binding 
domain. Additionally, the exchange of dystrophin repeats 23 or 24 (Dp260 R24Utr 
and Dp260 R23-24Utr) did not affect microtubule binding activity. The substitution 
of dystrophin repeat 20 (Dp260 R20Utr) resulted in a modest decrease in 
microtubule binding affinity, similar to that of the substitution of repeat 22 (Dp260 
R22-24Utr). However, the substitution of two or all repeats within the region of 
dystrophin repeats 20-22 (Dp260 R20-21Utr, Dp260 R20-22Utr, Dp260 R20-23Utr, 
Dp260 R21-24Utr, and Dp260 R20-24Utr) resulted in complete loss of specific 
microtubule binding activity (Figure 3-7A and Table 3-1). These data indicate that 
dystrophin repeats 20-22 are the most important for microtubule binding activity.  
Finally, constructs encoding only dystrophin repeats 20-22 or 20-24 failed 
to show any microtubule binding activity (Figure 3-8A and Figure 3-9). 
Interestingly, although both constructs displayed a single thermal transition when 
analyzed by DSF, we noticed a marked shift to higher denaturation temperatures 
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for both constructs (Figure 3-8B and Table 3-1). To more clearly illustrate 
differences in thermal stabilities, the data shown in Figure 3-10 are derivative 
plots of the data collected during a DSF experiment. When viewed in this 
manner, each peak of the curve more clearly defines the melting temperature(s) 
for the protein. Dys 20-22 and Dys 20-24 displayed a single melting temperature 
higher than any of the constructs shown in Figure 3-4 (Table 3-1), suggesting 
that the isolated repeats adopted a more thermally stable but microtubule non-
binding conformation. Interestingly, Utr R18-22Dys, which failed to bind 
microtubules even though it contains the microtubule binding domain of 
dystrophin, also exhibited a similar second DSF peak at the higher temperature 
suggesting that dystrophin repeats 20-24 adopt the same microtubule non-
binding conformation as they do in isolation when in the context of utrophin 
(Figure 3-10B and Table 3-1). This provides evidence as to why Utr R18-22Dys 
does not bind microtubules. By comparison, dystrophin lacked this second DSF 
peak and exhibited a single, broad melting temperature indicative of proper 
microtubule binding domain conformation. In summary, our data suggest that 
dystrophin repeats 20-22 are necessary but not sufficient for microtubule binding 
activity due to context-dependent folding of this region that is influenced by more 
distal sequences in dystrophin. 
Known microtubule binding proteins display a wide range of functions, 
including affecting tubulin polymerization dynamics, affecting microtubule 
depolymerization dynamics, bundling microtubules, and localizing microtubules 
to a specific location within the cell. To better understand the cellular role of 
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dystrophin binding to microtubules, we performed experiments to address the 
possibility that dystrophin plays a part in one or more of these functions.  
To determine if dystrophin affected tubulin polymerization, we performed 
tubulin polymerization assays in the presence or absence of dystrophin, utrophin, 
tau, and excess calcium (Figure 3-11A). Tau is a known enhancer of tubulin 
polymerization (Cleveland et al., 1977) whereas high calcium concentrations are 
known to decrease the rate of tubulin polymerization (Weisenberg, 1972; O’Brien 
et al., 1997). As expected, an increase in tubulin polymerization rate was seen in 
the presence of tau (5.64mOD/min) whereas excess calcium inhibited 
polymerization (0.03mOD/min). Whether or not dystrophin was present, tubulin 
showed no measurable difference in its polymerization rate (2.42mOD/min and 
2.46mOD/min for tubulin and tubulin plus dystrophin, respectively). The same 
held true when utrophin was present (2.38mOD/min). These data suggested that 
dystrophin had no effect on tubulin polymerization dynamics. 
 To test whether dystrophin affected microtubule depolymerization, tubulin 
was first polymerized into microtubules prior to switching the temperature to 4°C, 
which induces microtubule depolymerization. Over the course of 30 minutes, the 
rate of tubulin depolymerization (-8.75%/min) was no different than when 
dystrophin or utrophin was present (-8.01%/min and -6.92%/min, respectively) 
(Figure 3-11B). Tau partially reduced the rate of microtubule depolymerization (-
2.62%/min) whereas excess calcium neither decreased nor increased the rate of 
microtubule depolymerization (-8.75%/min). These data suggested that 
dystrophin had no effect on microtubule depolymerization dynamics. 
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 To test whether or not dystrophin bundled microtubules, we incubated 
both red and green fluorescently labeled microtubules alone, with dystrophin, 
with utrophin, or with tau, a known microtubule bundling protein (Lewis et al., 
1989). A positive bundling event was detected as yellow fluorescence, indicating 
the close apposition of red and green microtubules. While tau induced 
microtubule bundling (Figure 3-11C), neither dystrophin nor utrophin showed any 
induction of microtubule bundling. In addition to events in which tau bundled two 
individual microtubules (upper panel, arrows), there were also many instances in 
which large numbers of microtubules were bundled into large clusters (lower 
panel), which was not seen under any other conditions assayed. Together these 
data suggested that dystrophin had no microtubule bundling activity.  
 We and others have shown that subsarcolemmal microtubules are 
organized into a rectilinear lattice in the presence of dystrophin (Figure 2-2A, D, 
E), indicating that dystrophin plays a role in microtubule localization/organization. 
To determine how this localization occurred at the single microtubule level, we 
coupled either dystrophin or utrophin to fluorescent microparticles and imaged 
the dystrophin/microtubule or utrophin/microtubule interaction as free fluorescent 
tubulin was allowed to polymerize off immobile seeds (Hendricks et al., 2012). 
Kymographs of the data indicated that as a microtubule interacted with a 
dystrophin-coated microparticle, the microtubule paused as it interacted with 
dystrophin before depolymerizing (Figure 3-12A, C, E, G). In contrast, when a 
microtubule encountered a utrophin-coated microparticle, the microtubule 
immediately depolymerized (Figure 3-12B, D, F, G). We hypothesize that 
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dystrophin localized microtubules by acting as a guidepost to anchor 
microtubules to a specific location when directly encountering them, but not 
affecting their overall dynamics when in close proximity. In a muscle cell, this 
tethering would occur at the costamere where dystrophin localizes. 
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Discussion 
Microtubules are essential in all eukaryotic cells for mitosis, cell growth, 
and cell motility (Kirschner and Mitchison, 1986). In this study, we sought to 
further understand the properties of the dystrophin/microtubule interaction. We 
show for the first time that the dystrophin homolog utrophin exhibits no 
microtubule binding activity in vitro and that transgenic overexpression of 
utrophin on the mdx background fails to rescue microtubule lattice 
disorganization in vivo. It has already been shown that transgenic utrophin 
overexpression fails to localize nNOS to the sarcolemma (Li et al., 2010), 
providing the first evidence of a major functional difference between dystrophin 
and utrophin. Here, we have elucidated a second functional difference in regards 
to microtubule interaction, reinforcing the idea that while dystrophin and utrophin 
share many functions, they are not completely functionally interchangeable. 
Understanding the differences between these two proteins can better inform 
future therapeutic avenues of research, such as the use of miniaturized 
dystrophin constructs, by elucidating the domains within dystrophin necessary for 
full functionality. 
Our finding that dystrophin repeats 20-22 confer microtubule binding to 
full-length dystrophin, Dp260, and mini Dys but not to other dystrophin proteins 
containing these repeats, such as Dp140, Dys 15-24, and Dys 18-CT, or to 
utrophin when substituted for the homologous repeats, further adds to the 
evidence that dystrophin’s protein/protein interactions can be context-specific. 
We conclude that the presence of repeats 20-22 on their own or within the 
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context of full-length utrophin is not enough to recapitulate the microtubule 
binding of full-length dystrophin. 
Dystrophin repeats 20-22 have been previously reported to form a 
thermally stable, cooperative interaction (Mirza et al., 2010), supporting our 
finding that these repeats have a higher thermal denaturation temperature in 
isolation than the other portions of dystrophin or than that of full-length 
dystrophin. This work also cited repeats 16 and 17, the dystrophin repeats 
initially shown to localize nNOS, as another highly stable, cooperative interaction. 
The documented thermal cooperation of dystrophin repeats 20-22 also supports 
the idea that they work in concert to interact with microtubules, much as the 
thermally stable repeats 16 and 17 function together to localize nNOS to the 
sarcolemma. Additionally, our lab has provided evidence that while portions of 
dystrophin may display different thermodynamic characteristics when in isolation, 
full-length dystrophin displays its own thermodynamic characteristic instead of 
displaying those of each portion (Henderson et al., 2011). This indicates that the 
rod domain repeats impact one another and that when in isolation behave in a 
manner that may differ from their behavior when in the context of full-length 
protein. Due to size limitations, miniaturized gene therapy constructs are being 
researched for treating DMD. Our data suggest that deletion of one dystrophin 
domain may have consequences for the proper function of more distal domains. 
We also studied the effect of dystrophin on microtubule dynamics for the 
first time. We observed that dystrophin does not affect tubulin polymerization, 
microtubule depolymerization, or bundle microtubules. However, we did observe 
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a tethering effect when a single dynamic microtubule interacted with a stationary 
dystrophin molecule, providing a basis for the role of dystrophin in microtubule 
localization. To the best of our ability, we attempted to model the in vivo 
interaction of microtubules with dystrophin in an in vitro system in an attempt to 
understand how dystrophin localizes microtubules within striated muscle. To this 
end, coupling dystrophin to an immobile fluorescent microparticle was our way of 
recreating the normally stationary location of dystrophin at the costamere. Then, 
permitting tubulin to polymerize and analyzing the dystrophin/microtubule 
interaction when they came into proximity allowed us to visualize what we believe 
occurs in vivo. Based on the data presented, we hypothesize that dystrophin acts 
a molecular guidepost, localizing microtubules to the costamere where 
dystrophin resides.  
In summary, we have shown that repeats 20-22 of dystrophin directly 
interact with microtubules in a context-dependent manner resulting in microtubule 
lattice organization beneath the sarcolemma. Due to dystrophin acting as a 
molecular guidepost, microtubules become anchored to the costamere in muscle 
cells with microtubule lattice organization being the direct result of this. We have 
also shown that utrophin cannot interact with microtubules, illustrating a second 
functional difference between dystrophin and utrophin. 
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Figures 
 
Figure 3-1: Domain structure, microtubule binding properties, and 
differential scanning fluorimetry of dystrophin and utrophin. (A) Schematic 
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representation of dystrophin and utrophin proteins. Ovals represent spectrin-like 
repeats, diamonds represent hinge regions. Homologous repeats are aligned. 
Dystrophin repeats 15 and 19 do not have homologous repeats in utrophin. ABD, 
actin binding domain; nNOS, nNOS binding domain; DgBD, β-dystroglycan 
binding domain; NT, N-terminus; CT, C-terminus; CR, cysteine rich domain (B) 
Microtubule binding curve of dystrophin and utrophin. Dystrophin binds 
microtubules with high affinity (KD=0.33µM) whereas utrophin displays no specific 
microtubule binding. (C) DSF analyses of dystrophin and utrophin show that both 
unfold in a single transition at similar temperatures. 
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Figure 3-2: Domain structure of proteins analyzed. (A-B) Schematic 
representations of different dystrophin constructs tested in in vitro microtubule 
cosedimentation assays. Ovals and diamonds are as in Figure 3-1. Based on the 
unique domains present in the constructs that bind microtubules (shown in A), 
the microtubule binding domain lies within repeats 20-24.  
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Figure 3-3: Microtubule binding properties of constructs analyzed. 
Microtubule binding curves of all constructs shown in Figure 3-2. Only dystrophin, 
Dp260, and mini Dys show specific microtubule binding (KD=0.33µM, 0.26µM, 
and 0.38µM, respectively). No other construct shows specific microtubule 
interaction. 
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Figure 3-4: Differential scanning fluorimetry of constructs analyzed. DSF 
analysis of all constructs shown in A and B. Dp140, Dp116, Dys 15-24, and Dys 
18-CT display thermal denaturation curves different from that of full-length 
dystrophin, indicating that they are folded in a different manner. 
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Figure 3-5: Domain structure and microtubule binding properties of full-
length dystrophin and utrophin swap constructs. Substituting dystrophin 
repeats 20-24 for utrophin repeats 18-22 ablates specific microtubule binding. 
However, substituting utrophin repeats 18-22 for dystrophin repeats 20-24 does 
not confer microtubule binding to utrophin. Ovals and diamonds are as in Figure 
3-1. 
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Figure 3-6: Domain structure, microtubule binding properties, and 
differential scanning fluorimetry of Dp260 deletion constructs. (A) Dp260 
single repeat deletion constructs show no significant loss of microtubule binding 
activity, indicating that no single repeat functions as the microtubule binding 
domain of dystrophin. (B) DSF analysis shows that all constructs unfold in a 
single transition at similar temperatures to Dp260. 
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Figure 3-7: Domain structure, microtubule binding properties, and 
differential scanning fluorimetry of Dp260/utrophin swap constructs. (A) 
Dp260/Utrophin hybrid constructs with varying numbers of utrophin repeats 
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substituted into dystrophin repeats 20-24 reveals that repeats 20-22 are the most 
important for microtubule binding. Loss of dystrophin repeats 23 or 24 does not 
affect microtubule binding. Loss of repeat 20 or 22 results in a slight decrease in 
microtubule binding whereas losing two or all repeats within 20-22 ablates 
microtubule binding. Ovals and diamonds are as in Figure 3-1. (B) DSF analysis 
shows that all constructs unfold in a single transition at similar temperatures to 
Dp260. 
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Figure 3-8: Domain structure, microtubule binding properties, and 
differential scanning fluorimetry of isolated dystrophin repeats 20-22 and 
repeats 20-24. (A) Schematic representation of constructs assayed. Ovals are 
as in Figure 3-1. (B) DSF analysis shows that both constructs unfold in a single 
transition at higher temperatures than dystrophin. 
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Figure 3-9: Raw data for Figure 3-8. Coomassie stained SDS-PAGE gels of 
microtubule cosedimentation assays performed in the presence of Dys 20-22 
(upper) and Dys 20-24 (lower). Both constructs fail to cosediment with 
microtubules as tubulin dimer concentration is increased from 0 µM or 6 µM, 
indicating that no microtubule binding is occurring. S, supernatant (fraction not 
bound to microtubules); P, pellet (fraction bound to microtubules). 
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Figure 3-10: Differential scanning fluorimetry derivate curves. Derivative 
plots of DSF data for Dp140, Dp71, and Dys 20-24. Dp140 exhibits thermal 
characteristics of Dp71 and Dys 20-24. The higher thermal denaturation 
temperature of Dys 20-24 is indicative of the microtubule non-binding 
conformation. (B) Dystrophin does not exhibit a high thermal denaturation peak, 
indicating that repeats 20-22 are in a microtubule binding conformation. 
Dystrophin repeats 20-24 exhibit the high thermal denaturation temperature 
when placed within utrophin, indicating that utrophin does not provide the proper 
context for the microtubule binding domain of dystrophin to bind microtubules. 
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Figure 3-11: Effect of dystrophin and utrophin on tubulin polymerization, 
microtubule depolymerization, and microtubule bundling. (A) Tubulin 
polymerization assay. Tubulin polymerized at the same rate when alone, with 
dystrophin, or with utrophin (2.42 mOD/min, 2.46 mOD/min, and 2.38 mOD/min, 
respectively), indicating that dystrophin does not affect tubulin polymerization. 
Tau increased the rate of tubulin polymerization (5.64 mOD/min) and shortened 
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the microtubule nucleation phase whereas calcium drastically decreased the rate 
of polymerization (0.03 mOD/min). (B) Microtubule depolymerization assay. The 
rate of microtubule depolymerization was approximately the same when 
microtubules were incubated alone, with dystrophin, with utrophin, or with 
calcium (-8.75%/min, -8.01%/min, -6.92%/min, and -8.75%/min, respectively), 
indicating that dystrophin has no effect on microtubule depolymerization. Tau 
partially reduced the rate of microtubule depolymerization (-2.62%/min). (C) 
Microtubule bundling assay. Microtubules alone, with dystrophin, or with utrophin 
display no evidence of microtubule bundling as evidenced by the lack of yellow 
fluorescence. Tau exhibits microtubule bundling activity of individual microtubules 
as evidenced by yellow fluorescence (arrows, upper panel). Additionally, large 
tau/microtubule bundles were frequently observed (lower panel). Bar, 10 µm. 
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Figure 3-12: Effect of dystrophin and utrophin on microtubule localization. 
(A-B) Schematic representation of assay performed. Dystrophin (Dys, green) or 
utrophin (Utr, blue) coated YG microparticles and red fluorescent microtubule 
seeds were immobilized via anti-biotin to TIRF imaging chambers. Free red 
fluorescent tubulin was flowed into the chamber and the polymerization and 
depolymerization of microtubules as they interacted with the microparticles 
imaged over time. (C) Time lapse images of a direct dystrophin/microtubule 
interaction. As the microtubule interacts with dystrophin, its polymerization rate 
decreases as the microtubule becomes anchored to dystrophin. This interaction 
increases the time until catastrophe. Bar, 2 µm. (D) Time lapse images of a direct 
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utrophin/microtubule interaction. A microtubule that encounters a utrophin-coated 
microparticle does not become anchored and immediately undergoes 
catastrophe. Bar, 2 µm. (E) Kymograph of the data presented in C. (F) 
Kymograph of the data presented in D. (G) The dystrophin/microtubule (n=6) 
interaction time is significantly greater than the utrophin/microtubule (n=8) 
interaction time. Values shown are means with standard errors. ***, P < 0.001. 
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Tables 
 
Table 3-1: Differential scanning fluorimetry melting temperatures and 
microtubule dissociation constants for all constructs. 
Construct TM1 (°C) TM2 (°C) KD (µM) 
Dystrophin 46.6 ± 0.9   0.33 ± 0.08 
Dp260 46.4 ± 1.6   0.26 ± 0.04 
Dp140 39.3 ± 0.6 60.7 ± 3.1 No Specific Binding 
Dp116 40.6 ± 1.2 61.2 ± 0.6 No Specific Binding 
Dp71 36.3 ± 0.3   No Specific Binding 
Dys NT-17 44.8 ± 1.1   No Specific Binding 
Dys 10-19 44.7 ± 1.3   No Specific Binding 
Dys 15-24 33.2 ± 0.3 56.7 ± 0.6 No Specific Binding 
Dys 18-CT 38.9 ± 0.5 57.7 ± 0.5 No Specific Binding 
mini Dys 46.5 ± 0.6   0.38 ± 0.07 
µH2 Dys 48.0 ± 1.5   No Specific Binding 
µH3 Dys 48.3 ± 1.5   No Specific Binding 
Utrophin 43.1 ± 1.6   No Specific Binding 
        
Dp260 ΔR20 44.6 ± 2.0   0.47 ± 0.14 
Dp260 ΔR21 42.3 ± 3.9   0.49 ± 0.07 
Dp260 ΔR22 40.6 ± 3.2   0.34 ± 0.03 
Dp260 ΔR23 42.2 ± 2.7   0.39 ± 0.06 
Dp260 ΔR24 42.1 ± 0.6   0.60 ± 0.15 
        
Dp260 R20Utr 45.8 ± 1.0   0.84 ± 0.15 
Dp260 R20-21Utr 44.6 ± 0.2   No Specific Binding 
Dp260 R20-22Utr 43.4 ± 0.4   No Specific Binding 
Dp260 R20-23Utr 43.1 ± 0.3   No Specific Binding 
Dp260 R24Utr 46.7 ± 0.3   0.52 ± 0.17 
Dp260 R23-24Utr 46.7 ± 0.5   0.35 ± 0.09 
Dp260 R22-24Utr 44.9 ± 0.5   1.13 ± 0.19 
Dp260 R21-24Utr 46.3 ± 6.0   No Specific Binding 
Dp260 R20-24Utr 46.5 ± 0.4   No Specific Binding 
        
Dys 20-22   62.7 ± 4.2 No Specific Binding 
Dys 20-24   63.0 ± 1.8 No Specific Binding 
        
Dys R20-24Utr 46.7 ± 1.2   No Specific Binding 
Utr R18-22Dys 43.0 ± 0.6 58.0 ± 1.1 No Specific Binding 
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Chapter Four 
Conclusions and Discussion 
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Dystrophin is thought to stabilize the sarcolemma against contraction-
induced injuries that occur as a result of normal muscle contraction. The exact 
mechanism through which dystrophin performs this role was initially thought to be 
by linking the actin cytoskeleton to the extracellular matrix allowing for radial 
force transduction and reduced membrane damage. However, studies have 
shown that dystrophin directly interacts with intermediate filament proteins 
(Bhosle et al., 2006) and microtubules (Prins et al., 2009), indicating that 
dystrophin may protect against contraction-induced injury via multiple 
cytoskeletal interactions. Since dystrophin interacts with microtubules whereas its 
homolog utrophin does not, we sought to determine the physiological relevance 
of the dystrophin-microtubule interaction and whether any pathologies can be 
directly attributed to the lack of this interaction as seen in DMD patients and the 
mdx mouse.  
Sarcolemmal nNOS has been implicated in effecting vasodilation to 
increase oxygen delivery to muscle during contraction. Mice lacking nNOS 
exhibit reduced cage activity after mild exercise (Kobayashi et al., 2008), which is 
exacerbated in mdx mice presumably due to the additional lack of dystrophin. We 
have shown here that the Fiona-mdx mouse, which transgenically overexpresses 
utrophin, fails to fully rescue this loss of activity. We conclude that utrophin 
cannot fully compensate for dystrophin in regards to exercise-induced inactivity 
and that this may partially be explained through a lack of nNOS localization to the 
sarcolemma. However, since activity is partially recovered from the mdx mouse 
in the Fiona-mdx mouse, another aspect of the mdx mouse beyond the lack of 
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nNOS localization to the sarcolemma must contribute to its lack of activity after 
mild exercise. Since the recovery seen in the mini-Dys-TG-mdx mouse is 
comparable to the Fiona-mdx mouse, we believe that the level of recovery seen 
in the Fiona-mdx mouse is not a utrophin-specific phenomenon, but rather that 
the loss of full-length utrophin or full-length dystrophin below endogenous 
dystrophin protein levels is the main cause of activity loss.  
The exact physiological consequences of microtubule derangement are 
yet to be fully elucidated, but recent work has shown that the perturbed 
microtubule lattice in the dystrophin-deficient mdx mouse appears to exacerbate 
the dystrophic phenotype (Khairallah et al., 2012). In this study, the authors show 
that the loss of force generation seen in the mdx mouse upon repeated eccentric 
contractions can be greatly ameliorated when microtubules are depolymerized 
using colchicine. They postulate that perturbation of the microtubule lattice may 
contribute to the loss of force generation and that simply reducing overall 
microtubule abundance can improve performance. Therefore, therapies 
attempting to ameliorate DMD and BMD patients’ symptoms may need to 
account for the role that microtubule lattice disorganization plays in muscle 
weakness. We show for the first time that transgenic utrophin overexpression is 
incapable of preventing loss of torque production specifically in anterior muscles 
and that this is a microtubule-related phenotype (Chapter 2). We intend to use 
our newly generated dystrophin transgenic mouse lines in which the microtubule 
binding domain has been ablated (Appendix) to further evaluate direct 
physiological consequence of microtubule lattice disorganization.  
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Additionally, microtubules have been shown to be integral in the formation 
of myotubes from myoblasts during muscle development and differentiation 
(Saitoh et al., 1988; Chang et al., 2002; Perez et al., 2002). The Golgi apparatus 
requires proper microtubule organization in muscle for both proper localization 
and proper vesicular trafficking (Ralston et al., 1999, 2001). That mdx and Fiona-
mdx mice survive to adulthood would seem to argue that microtubule 
organization is not required for myotube formation whereas the Golgi is intimately 
dependent on microtubule organization, underscoring the different roles that 
microtubules have within muscle cells and highlighting how much research is still 
necessary to fully understand the interplay of these processes. 
We have mapped the microtubule binding domain of dystrophin to 
spectrin-like repeats 20-22 of the central rod domain (Chapter 3). These repeats 
have been previously reported to adopt a thermally stable, highly cooperative 
conformation when expressed in isolation (Mirza et al., 2010), corroborating our 
findings. When spectrin-like repeats 20-22 are swapped for the homologous 
repeats from utrophin, microtubule binding is ablated. However, swapping these 
repeats into utrophin does not confer microtubule binding activity, indicating that 
these repeats are not sufficient for microtubule binding. This context-specific 
interaction of dystrophin and microtubule also holds true for dystrophin and 
nNOS, indicating that flanking regions of the dystrophin protein are required for 
the proper function of the protein as a whole.  
Context-specific interactions between dystrophin and other binding 
partners have been previously reported. We recently demonstrated that the 
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dystrophin/actin interaction is enhanced by the carboxy-terminal third of 
dystrophin even though no direct dystrophin/actin interaction can be measured 
for this region (Henderson et al., 2012). Additionally, the second and third alpha 
helices of dystrophin repeat 16 are necessary but not sufficient for nNOS 
localization to the sarcolemma (Lai et al., 2013); when these helices were 
swapped into the homologous region of utrophin, no nNOS localization was 
observed. Many therapies in development tend to focus on miniaturized 
dystrophin constructs in which large regions of the rod domain deemed less 
important are removed. Our results argue that these approaches may be less 
effective due to the cooperative influences between multiple domains present in 
dystrophin. In support of this, we have shown that full-length dystrophin displays 
thermodynamic characteristics unique from those reported by individual domains 
(Henderson et al., 2011). 
In addition to delineating the minimal microtubule binding domain, we 
have shown for the first time how dystrophin organizes the subsarcolemmal 
microtubule lattice. While dystrophin does not affect tubulin polymerization, 
microtubule depolymerization, or bundle microtubules it appears to localize 
microtubules to the sarcolemma by acting as a molecular guidepost (Chapter 3). 
When actively polymerizing microtubules encounter a dystrophin molecule, they 
become anchored and pause before continuing to polymerize. This anchorage 
helps explain how the presence of dystrophin results in subsarcolemmal 
microtubule organization. Lack of dystrophin, as in the mdx mouse, or the 
overexpression of utrophin at the sarcolemma, as in the Fiona-mdx mouse, does 
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not allow for proper microtubule guidance and thus results in lattice 
disorganization. 
In conclusion, we have shown: (1) that spectrin-like repeats 20-22 in 
dystrophin are necessary but not sufficient to organize the subsarcolemmal 
microtubule lattice, (2) that microtubule organization is achieved through 
dystrophin acting as a molecular guidepost to orient microtubules, (3) that the 
microtubule binding activity of dystrophin is not conserved in utrophin, (4) that 
reduced cage activity after mild exercise in the Fiona-mdx and mini-Dys-TG-mdx 
mice is an nNOS-associated phenotype, and (5) that reduced torque production 
in anterior crural muscles of the Fiona-mdx mouse is a microtubule-associated 
phenotype. Additionally, we have generated a transgenic mouse model 
expressing a dystrophin lacking microtubule binding activity (Appendix) to further 
investigate the specific contributions of microtubule disorganization on DMD. 
 
 
 
 
 
 
 
 
 
 
84 
 
Chapter Five  
Materials and Methods 
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Mice 
All animals were housed and treated in accordance with the standards set 
by the University of Minnesota Institutional Animal Care and Use Committee. 
Fiona-mdx mice were kind gifts from Dr. Kay E. Davies (University of Oxford). 
Dys-TG-mdx and mini-Dys-TG-mdx mice were kind gifts from Dr. Jeffrey S. 
Chamberlain (University of Washington).  
 
Establishment of Transgenic Mice 
The human skeletal α-actin (HSA) promoter was cloned in place of the 
cytomegalovirus promoter in the Gateway version of the mammalian expression 
vector pcDNA, pDEST40. This new plasmid (pDEST-HSA) was used to create a 
transgene with the Dys R20-24Utr construct, which was already built in the 
pENTR/D-TOPO vector using the methods described below. pDEST-HSA-Dys 
R20-24Utr DNA was restriction digested to linearize the transgene (KasI and 
NaeI), gel extracted, and sent for pronuclear injection at the Mouse Genetics 
Core at The Scripps Research Institute. Transgenic founder mice were identified 
by PCR using HSA-specific primers (Forward: 5’-GTC AGG AGG GGC AAA 
CCC GC-3’, Reverse: 5’-GTC GCT GCC CTT CTC GAG CC-3’, Product Size: 
187bp). Transgenic founder mice were crossed with C57Bl/10 mice to check for 
transgene transmission. Dystrophin protein expression was assessed in several 
different muscles from each transgene transmitting line once crossed onto the 
mdx background using quantitative Western blotting. Three lines transmitted the 
transgene and had detectable protein expression as detailed in Table A-1.  
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Reagents 
Anti-α-tubulin (DM1A, 1:200), anti-α-tubulin (B512, 1:1000), anti-β-tubulin 
(D66, 1:1000), anti-pan-actin (C4, 1:1000), anti-laminin (L9393, 1:1000), anti-
FLAG (M2, 1:2000), and anti-biotin (BN-34, 1:10) antibodies were purchased 
from Sigma Aldrich. Anti-dystrophin (Dys1, 1:50), anti-β-dystroglycan (NCL-b-
DG, 1:100), anti-α-sarcoglycan (NCL-a-SG, 1:100), and anti-γ-sarcoglycan (NCL-
g-SG, 1:100) antibodies were purchased from Leica. Anti-utrophin (8A4, 1:50) 
antibody was purchased from Santa Cruz Biotechnology. Anti-α-dystroglycan 
(IIH6C4, WB: 1:500, IF: 1:100) and anti-syntrophin (1351, 1:100) antibodies were 
purchased from Millipore. Anti-dystrobrevin (23, 1:100) antibody was purchased 
from BD Biosciences. Anti-nNOS (Z-RNN3, 1:150) antibody, Alexa Fluor 
secondary antibodies (1:250), Alexa Fluor α-bungarotoxin (1:500), and SYPRO 
Orange (1:1000) were purchased from Invitrogen. Wheat germ agglutinin 
agarose beads were purchased from Vector Laboratories. Pre-formed 
microtubules, tubulin, red fluorescent tubulin, green fluorescent tubulin, 
biotinylated tubulin, tau, and paclitaxel were purchased from Cytoskeleton. 
Fluoresbrite fluorescent YG COOH microparticles (polystyrene, 1µm diameter) 
and PolyLink protein coupling kit were purchased from Polysciences. Primers 
were purchased from Integrated DNA Technologies. 
 
Muscle Fiber Imaging 
Extensor digitorum longus muscles were harvested from profusion-fixed 
mice and immunostained for α-tubulin (DM1A). Profusion media (50mM PIPES, 
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5mM EGTA, 2mM MgSO4, 10% DMSO, 0.1% Triton X-100, pH 6.8) containing 
4% paraformaldehyde was previously described (Hardham, 1987). Muscles were 
further post-fixed in 4% paraformaldehyde in phosphate buffered saline (PBS: 
8mM NaH2PO4, 42mM Na2HPO4, 150mM NaCl, pH 7.5) for 48 hours while 
rotating. Single muscle fibers or bundles of two or three muscle fibers were 
mechanically teased apart and incubated with anti-α-tubulin overnight with 
rotation. Goat anti-mouse secondary antibody coupled to Alexa Fluor 488 or 568 
was used for visualization. Fibers were mounted on slides using SlowFade Gold 
antifade reagent with DAPI (Invitrogen) to visualize nuclei. Fibers were imaged 
on the Olympus FluoView FV1000 with the 60X oil immersion objective using the 
accompanying software. Z-stacks of two to three sarcolemmal images were 
maximally projected using ImageJ. Brightness and contrast were adjusted using 
Adobe Photoshop. 
 
Mouse Activity Cage Measurements 
Exercise-induced inactivity was assessed as previously described 
(Kobayashi et al., 2008) with the following modifications. Mice were acclimated to 
the treadmill for three consecutive days prior to activity cage assessments. 
Acclimation consisted of 5 minutes at 0 m/min followed by 5 minutes at 9 m/min 
at 0° incline. On the fourth day, baseline voluntary activity was assessed for 30 
minutes prior to exercise using activity cages (AccuScan Instruments Inc.). Mice 
were then placed on the treadmill set at 15° decline. Mice were acclimated to the 
treadmill for 5 minutes at 0 m/min. Without the use of electrical shock, mice were 
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encouraged to walk for 5 minutes at 5 m/min followed by 10 minutes at 15 m/min. 
After exercise, mice were placed back in the same activity cages and activity 
monitored for 30 minutes after exercise. 
 
Ex Vivo EDL Force Measurements 
 The contraction-induced injury protocol consisted of ten eccentric 
contractions performed on isolated extensor digitorum longus (EDL) muscles 
harvested from mice anesthetized with sodium pentobarbital (100 mg/kg). EDL 
muscles were secured to a force transducer with 5-0 suture in a 1.5 mL bath 
assembly and incubated at 25°C in an oxygenated (95% O2) Krebs-Ringer 
bicarbonate buffer solution. Eccentric contractions were performed as 
follows. EDL muscles were passively shortened to 95% resting length 
and then stimulated for 200ms while the muscle was simultaneously lengthened 
to 105% resting length at 0.5 lengths/s. Each eccentric contraction was 
separated by three minutes of rest before performing the next eccentric 
contraction. Force production was plotted as a percentage of initial force.  
 
In Vivo Muscle Torque Measurements 
 Mice were anesthetized with 0.2 mg/kg fentanyl citrate, 10 mg/kg 
droperidol, and 5mg/kg diazepam. Electrodes were placed on either side of the 
peroneal nerve of the left hind limb and the left paw placed into a mechanical foot 
lever. Torque was measured over frequencies ranging from 20 to 400Hz to 
determine optimal frequency of excitation. Initial torque production was measured 
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by stimulating muscles for 150ms at 250Hz. The voltage was adjusted between 
3-5V to achieve maximal isometric torque. The muscles were injured by 70 
electrically-induced eccentric contractions of 150ms each. Each eccentric 
contraction took place such that the foot was passively moved from 0° to 19° of 
dorsiflexion relative to the tibialis anterior muscle for 100ms followed by an 
additional movement from 19° of dorsiflexion to 19° of plantarflexion at an 
angular velocity of 2°/ms for 50ms. Torque about the ankle joint was measured 
for each eccentric contraction and plotted as a percentage of initial torque 
production.  
 
Neuromuscular Junction Imaging 
 Gastrocnemius muscles from each mouse line were cryopreserved in 
OCT and 20µm longitudinal sections cut. Sections were fixed in 4% 
paraformaldehyde in PBS for ten minutes and subsequently washed three times 
in PBS for five minutes each. Alexa Fluor 488 α-bungarotoxin was incubated on 
the sections for 30 minutes at 37°C. Sections were washed three times in PBS 
for five minutes each and slides sealed using SlowFade Gold antifade reagent 
with DAPI to visualize nuclei. Images were acquired on a Deltavision PersonalDV 
deconvolution microscope equipped with a 100X 1.40 NA oil objective. 
 
Immunofluorescence 
 Quadriceps muscles from each mouse line were cryopreserved in OCT 
and 10µm transverse sections cut. Sections were fixed in 4% paraformaldehyde 
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in PBS for ten minutes and subsequently washed three times in PBS with 0.1% 
Triton for five minutes each. Primary antibodies were incubated overnight at 4°C 
in a humidified chamber. The next day, slides were washed three times in PBS 
with 0.1% Triton for five minutes each and goat anti-mouse or anti-rabbit 
secondary antibody coupled to Alexa Fluor 488 or 568 was incubated on the 
sections for 30 minutes at 37°C. Sections were washed three times in PBS with 
0.1% Triton for five minutes each and slides sealed using SlowFade Gold 
antifade reagent with DAPI to visualize nuclei. Images were acquired on a 
Deltavision PersonalDV deconvolution microscope equipped with a 40X 1.35 NA 
oil objective. 
 
Cloning 
All dystrophin and utrophin plasmid constructs were initially inserted and 
sequence verified in the Gateway entry vector pENTR/D-TOPO (Invitrogen) after 
PCR amplifying them from existing N-terminally FLAG-tagged pFastBac1 
constructs from previous studies (Rybakova et al., 2002, 2006; Prins et al., 2009; 
Henderson et al., 2010, 2011). All PCRs were performed using PfuII Ultra HS 
polymerase (Stratagene). Once verified, entry vectors were recombined into the 
Gateway insect cell destination vector, pDEST8, using LR Clonase II (Invitrogen) 
and subsequently expressed in Sf9 insect cells using the Bac-to-Bac system 
(Invitrogen).  
Deletion constructs were built as previously described (Imai et al., 1991). 
Briefly, PCR primers were designed such that they amplified the entire plasmid 
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except the region being deleted. These linear PCR products were then 
circularized via the addition of T4 polynucleotide kinase and T4 DNA ligase (New 
England Biolabs) and sequence verified. Multiple rounds of deletion were 
performed if necessary to create the desired construct. 
Dystrophin/utrophin hybrid constructs were built as follows. Briefly, PCR 
primers were designed to amplify the entire dystrophin plasmid except the 
repeats being exchanged with primers containing 15 nucleotide overhangs 
homologous to the ends of the utrophin repeats being substituted in. Additionally, 
the homologous utrophin repeats being substituted in were PCR amplified with 
primers containing 15 nucleotide overhangs homologous to the dystrophin 
repeats flanking the hybrid region. These two PCR products were mixed in 
equimolar ratios and assembled into a single vector using the Gibson Assembly 
Master Mix (New England Biolabs). These vectors were sequence verified, 
recombined into pDEST8, and expressed as described above. 
 
Protein Expression and Purification 
FLAG-tagged dystrophin and utrophin proteins were expressed and 
purified in Sf9 insect cells using the Bac-to-Bac protocol (Invitrogen). Briefly, 
recombinant baculoviral DNA was transfected into a small culture of Sf9 insect 
cells using CellFectin II (Invitrogen). Four days later, the media containing the 
recombinant baculovirus was harvested and the transfected cells were analyzed 
for protein expression by anti-FLAG Western blot. Once expression was verified, 
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large cultures were incubated for three days with amplified baculovirus before 
being harvested for protein purification.  
For purification, cells were lysed using 1% Triton X-100 in phosphate 
buffered saline containing protease inhibitors (100nM aprotinin, 1mM 
benzamidine, 10µM E-64, 10µM leupeptin, 1mM pepstatin A, and 1mM 
phenylmethanesulfonylfluoride) and protein purified using M2 FLAG affinity 
agarose (Sigma) as previously described (Prins et al., 2009; Henderson et al., 
2010, 2011). Proteins were dialyzed into microtubule buffer (50mM HEPES, 
50mM KCl, 1mM MgCl2, 1mM EGTA, pH 7.5) overnight at 4°C before being 
concentrated and used in in vitro microtubule cosedimentation assays, DSF 
analyses, and tubulin dynamics assays. 
 
In vitro Microtubule Cosedimentation Assay 
For in vitro microtubule cosedimentation assays, 0.75µM dystrophin or 
utrophin proteins were incubated with pre-formed microtubules ranging from 0µM 
to 6µM tubulin dimer for 30 minutes at room temperature. Reactions were then 
centrifuged at 100,000 × g for 30 minutes at room temperature. The supernatant 
was collected and an equal volume of buffer used to resuspend the pelleted 
microtubules and interacting protein. Equivalent volumes of supernatant and 
pellet were run side-by-side using SDS-PAGE, stained using Coomassie blue, 
and imaged and analyzed via densitometry using the Odyssey infrared scanner 
(Li-cor). Fraction of protein in the pellet was plotted against the concentration of 
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tubulin dimer for each sample and the data fit to a one site saturation binding 
curve using SigmaPlot (Systat Software).  
 
Differential Scanning Fluorimetry 
For DSF, the dye SYPRO Orange was incubated with each protein while 
fluorescence emission was collected in a real time PCR instrument (iCycler, Bio-
Rad) as the temperature of the solution was raised from 20°C to 90°C. Data were 
normalized from 0 to 1 fraction protein unfolded. A curve was fit to the 
exponential portion of the data using a two-state transition algorithm (Henderson 
et al., 2011), the inflection point of which was calculated as the melting 
temperature of that protein. Dp140, Dys 15-24, and Dys 18-CT were fit to a 
three-state transition algorithm to account for the two inflection points present. 
Dp116 could not be fit to either transition algorithm and thus the two melting 
temperatures were determined by fitting each portion of the data to separate two-
state transition algorithms. Derivative plot data values were extracted directly 
from the iCycler, and scaled such that they ranged from 0 to 1. 
 
Tubulin Dynamics Assays 
Tubulin polymerization was carried out in a microplate reader (SpectraMax 
Plus384, Molecular Devices) at 37°C for two hours in the presence or absence of 
each protein assayed according to the manufacturer’s protocol (Cytoskeleton). 
Proteins of interest were used at 0.65µM while tubulin was used at 3mg/mL 
(~27µM tubulin dimer). For excess calcium, 2mM CaCl2 was included in the 
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reaction to compensate for the presence of EGTA (Schoenmakers et al., 1992). 
The increase in optical density at 340nm was recorded as a measure of 
increased presence of polymerized microtubules. The logarithmic growth portion 
of each reaction was used to calculate the rate of polymerization via linear 
regression using SigmaPlot (Systat Software). 
Microtubule depolymerization was carried out by first polymerizing tubulin 
as above. Buffer or the protein being assayed was then added to the reaction 
and the temperature switched to 4°C. Loss of the presence of microtubules was 
measured in the same manner as above over 30 minutes, with a decrease in 
optical density at 340nm indicating depolymerization of microtubules. The 
logarithmic portion of each reaction was used to calculate the rate of 
depolymerization via linear regression. 
To assay for microtubule bundling, equivalent amounts of red and green 
fluorescent tubulin were individually induced to polymerize into microtubules and 
then combined in equivalent amounts in the presence or absence of the protein 
being assayed prior to incubation at room temperature for 30 minutes. Final 
tubulin dimer concentration was 6µM and proteins of interest were at 0.75µM. 
Reactions were diluted 1:200 in imaging buffer (80mM PIPES, 2mM MgCl2, 
0.5mM EGTA, 30% glycerol, 0.5% glutaraldehyde, pH 6.9) before images were 
acquired on a Deltavision PersonalDV deconvolution microscope equipped with a 
60X 1.42 NA oil objective with yellow fluorescence indicative of a positive 
bundling event.  
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Protein/microtubule direct interaction studies were performed as 
previously described (Hendricks et al., 2012). Briefly, COOH YG microparticles 
were conjugated to biotinylated-BSA and either dystrophin or utrophin using the 
PolyLink protein coupling kit according to the manufacturer’s protocol. Protein-
coupled YG microparticles and red fluorescent biotinylated-tubulin containing 
microtubule seeds were hybridized to a total internal reflection fluorescence 
(TIRF) imaging chamber using anti-biotin. After hybridization, the chamber was 
rinsed with BRB80 (80mM PIPES, 1mM MgCl2, 1mM EGTA, pH 6.9). Tubulin 
polymerization was initialized by adding 10µM tubulin (9:1 unlabeled:red 
fluorescent tubulin) in imaging buffer (50mM KCl, 20mM glucose, 0.15% methyl 
cellulose, 10 µg/mL casein, 2 µg/mL glucose oxidase, 1 µg/mL catalase, 10mM 
DTT, 3mM GTP, 1% Tween). TIRF microscopy was performed using a Nikon 
Eclipse Ti microscope with Nikon CFI Apochromat 100X 1.49 NA oil objective. An 
Andor iXon3 EM-CCD camera fitted with a 2.5X projection lens was used for 
image acquisition. Images were collected every 5 seconds and analyzed using 
ImageJ. COOH YG microparticles bound to utrophin were pseudo-colored blue 
using ImageJ. 
 
Wheat Germ Agglutinin Dystrophin-Glycoprotein Complex Enrichment 
 Muscle tissue was harvested from each mouse line, snap frozen in liquid 
nitrogen, ground with a mortar and pestle, and lysed for thirty minutes in 1% 
Triton X-100 in phosphate buffered saline containing protease inhibitors (100nM 
aprotinin, 1mM benzamidine, 10µM E-64, 10µM leupeptin, 1mM pepstatin A, and 
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1mM phenylmethanesulfonylfluoride). Lysates were clarified by centrifugation, an 
aliquot collected as a starting lysate sample, and the remaining lysate incubated 
with wheat germ agglutinin conjugated agarose beads overnight at 4°C while 
rotating. The next day, the lysate was removed from the beads and kept as the 
void fraction. The beads were washed three times with 1% Triton X-100 in 
phosphate buffered saline. After washing, the beads were boiled in 2X Laemmli 
sample buffer (5% sodium dodecyl sulfate, 192mM sucrose, 108mM Tris, 710mM 
β-mercaptoethanol, 0.0007% bromophenol blue) for five minutes. This fraction 
was taken as the elution. 
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Appendix 
Generation of a transgenic mouse model expressing a dystrophin lacking 
microtubule binding activity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Joseph Belanto performed all experiments. 
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Chapter 3 outlines the delineation of the minimal microtubule binding 
domain of dystrophin, the data from which we used to generate a transgenic 
mouse model expressing a dystrophin-utrophin hybrid protein in which the 
microtubule binding domain of dystrophin was replaced with the homologous 
region of utrophin (Dys R20-24Utr). This hybrid protein retains the nNOS binding 
domain (Lai et al., 2009) but fails to bind microtubules (Figure 3-5). Dys R20-24Utr 
was engineered under the control of the human skeletal alpha-actin promoter, 
restricting expression to skeletal muscles, the same strategy used for generation 
of the Fiona-mdx, the Dys-TG-mdx, and the mini-Dys-TG-mdx mouse models 
(Figure A-1). Transgenic founder mice have been produced and bred, the details 
of which are outlined in Table A-1.  
Our current mouse lines express 15% (Ln2), 30% (Ln22), and 160% (Ln4) 
levels of WT dystrophin on the mdx mouse background (Figure A-2 and Table A-
1). Line Ln22 is line Ln2 bred to be homozygous for the transgene. A last 
transgenic mouse line (Ln3) is still being bred onto the mdx background. These 
mice will be utilized in future experiments to further delineate phenotypes specific 
to the loss of microtubule organization. Initial characterization of the Ln22-mdx 
and Ln4-mdx mouse lines is detailed below. 
To initially determine that the transgenic dystrophin protein was properly 
localized within muscle and that it had integrated into the DGC, we performed 
wheat germ agglutinin (WGA) chromatography to enrich whole muscle lysates for 
DGC components. WGA is a lectin which binds to N-acetyl-D-glucosamine and 
sialic acid, both of which are abundant on the surface of α-dystroglycan. We 
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show that in both Ln22-mdx and Ln4-mdx mice, transgenic dystrophin 
incorporates into the DGC as evidenced by its presence in the elution fraction of 
the WGA enrichment (Figure A-3). Additionally, known DGC components such as 
the dystroglycans and syntrophin are present in the WGA elution fraction.  
 We next sought to determine whether DGC components showed proper 
sarcolemmal localization in our transgenic mice. Dystrophin, α-dystroglycan, β-
dystroglycan, α-sarcoglycan, γ-sarcoglycan, dystrobrevin, syntrophin, nNOS, and 
laminin show sarcolemmal localization in WT mice (Figure A-4). Utrophin levels 
in WT mice are reduced compared to mdx mice, which upregulate utrophin in the 
absence of dystrophin. Utrophin in mdx mice shows greater sarcolemmal 
localization than in any other line. Transgenic line Ln22-mdx and Ln4-mdx show 
presence of all DGC components at the sarcolemma, with Ln22-mdx mice 
showing relatively reduced levels of all components, except utrophin, as 
compared to WT and Ln4-mdx mice. Ln22-mdx mice show increased levels of 
utrophin at the sarcolemma as compared to WT but lower than that seen in mdx 
mice, most likely due to the lower dystrophin expression of this line. These data 
indicate that the low levels of dystrophin present in Ln22-mdx mice partially 
restores the DGC, but not to levels present in WT mice whereas Ln4-mdx mice 
show sarcolemmal localization of all DGC components comparable to WT. 
Additionally, we analyzed the patterning of the neuromuscular junction in 
our transgenic mice. Like WT mice, we find that Ln22-mdx and Ln4-mdx mice 
show the pretzel-like patterning of the neuromuscular junction (Figure A-5). This 
is in contrast to the grape-like patterning of the mdx neuromuscular junction. 
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These data indicate to us that even relatively low levels of dystrophin present in 
Ln22-mdx mice are sufficient to rescue the disorganized neuromuscular junction 
patterning of the mdx mouse. 
Lastly, we analyzed the subsarcolemmal microtubule lattice organization 
in our transgenic mice. As shown in Figure 2-2, the WT subsarcolemmal 
microtubule lattice adopts a rectilinear lattice organization whereas the mdx 
microtubule lattice lacks such organization (Figure A-6). The microtubule lattice 
of the Ln22-mdx mouse appears disorganized while the Ln4-mdx mouse appears 
somewhat intermediate between organized and disorganized. While we have 
shown that the transgene used to generate our mice lacks any in vitro 
microtubule binding activity (Figure 3-5), this does not preclude the hypothesis 
that reintroducing the other muscle stabilizing functions of dystrophin allows for 
partial rescue of microtubule lattice morphology.  
 Taken together, all current data for our transgenic mice suggest that they 
are good model for elucidating specific phenotypes of the mdx mouse specifically 
related to lack of WT microtubule lattice organization.  
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Figures 
 
 
 
 
Figure A-1: Plasmid map of construct used to generate transgenic mice.  
Constructs used to generate transgenic mice expressing a muscle-specific 
dystrophin incapable of binding microtubules. Ovals represent spectrin-like 
repeats, diamonds represent hinge regions. Red and yellow represent portions of 
dystrophin whereas blue represents portions of utrophin. HSA, human skeletal α-
actin promoter; NT, N-terminus; CT, C-terminus; CR, cysteine rich domain.  
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Figure A-2: Western blot of Ln22-mdx and Ln4-mdx transprotein 
expression. Dystrophin levels in Ln22-mdx mice is approximately 30% of WT 
levels whereas dystrophin levels in Ln4-mdx mice is approximately 160% of WT 
levels. Utrophin levels are elevated in mdx mice as compared to WT levels, but 
are reduced in the presence of transgenic dystrophin. Tubulin and actin shown 
as loading controls. 
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Figure A-3: Wheat germ agglutinin enrichment of DGC components in Ln22-
mdx and Ln4-mdx mice. Transgenic dystrophin incorporates into the DGC as 
evidenced by its presence in the elution fraction of the WGA enrichment. The 
dystroglycans and syntrophin are also present in the elution fraction, with their 
relative abundance proportional to the levels of dystrophin present in each 
mouse line. S, starting lysate; V, void fraction not bound to WGA beads; E, 
elution fraction from WGA beads. 
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Figure A-4: Immunofluorescence analysis of Ln22-mdx and Ln4-mdx mice. 
Dystrophin, utrophin, α-dystroglycan, β-dystroglycan, α-sarcoglycan, γ-
sarcoglycan, dystrobrevin, syntrophin, nNOS, and laminin immunofluorescent 
localization in WT, mdx, Ln22-mdx, and Ln4-mdx mice. Dystrophin is absent in 
mdx mice. Utrophin levels are upregulated in mdx mice as compared to other 
lines. Ln22-mdx and Ln4-mdx mice show presence of all DGC components at the 
sarcolemma. Bar, 20µm. 
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Figure A-5: Neuromuscular junction imaging in Ln22-mdx and Ln4-mdx 
mice. (A) Neuromuscular junction morphology in a WT mouse resembles a 
pretzel. (B) This morphology is lost in the mdx mouse and instead appear as a 
cluster of grapes. (C) The Ln22-mdx mouse shows rescued neuromuscular 
junction morphology. (D) The Ln4-mdx mouse shows rescued neuromuscular 
junction morphology. Bar, 5µm. 
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Figure A-6: Extensor digitorum longus muscle sarcolemmal microtubule 
imaging in Ln22-mdx and Ln4-mdx mice. (A) When dystrophin is present (WT), 
microtubules are organized into a rectilinear lattice beneath the sarcolemma. 
Image is identical to Figure 2-2A. (B) In the absence of dystrophin (mdx), the 
microtubule lattice becomes disordered. (C-D) Transgenic expression of 
dystrophin lacking the microtubule binding domain does not fully rescue the 
disorganized microtubule lattice. Single extensor digitorum longus muscle fibers 
were mechanically teased from profusion fixed mice and immunostained for 
tubulin and counterstained with DAPI to visualize nuclei. Bar, 20µm. 
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Tables 
Mouse 
ID 
Date Of 
Birth  
Sex 
Transgene 
Transmission? 
Transprotein 
Expression? 
Mouse Line 
1 7/31/2012 F Yes Yes Ln3 
4 7/31/2012 M Yes No Ln1 
5 7/31/2012 M Never Bred - - 
7 7/31/2012 F Never Bred - - 
10 7/31/2012 F Never Bred - - 
13 7/31/2012 M Yes Yes (15% WT) Ln2 
    Yes (30% WT) Ln22 
16 7/31/2012 F Yes Yes (160% WT) Ln4 
21 8/28/2012 F No - - 
23 8/28/2012 M No - - 
25 8/28/2012 M Never Bred - - 
 
Table A-1: Summary of transgenic Dys R20-24Utr founder mice received, 
transgene transmission, and transprotein expression. Transgenic line 2 was 
bred to be homozygous for the transgene (Ln22) to increase the level of protein 
expression. Transgenic line 3 has not been bred onto the mdx background yet, 
therefore no protein expression level is listed.  
 
 
 
 
 
 
 
 
 
 
